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Summary 
 
Leishmania infantum is the causative agents of zoonotic visceral leishmaniasis, a 
fatal disease if left untreated. In Southern Europe, the number of HIV/Leishmania 
infantum co-infections is increasing and becomes an emerging concern for the public 
health. Dogs represent the main reservoir of this parasite. In order to control canine 
leishmaniasis, an early diagnosis system is needed because dogs are capable to 
transmit the parasite, before showing any symptoms of the disease. Here fore, cDNA 
expression libraries were screened with sera of infected dogs. We selected several 
antigens reacting with the sera. These were different histones, ribosomal and 
mitochondrial proteins. Four of them were subcloned into expression plasmids, and 
recombinantly expressed in E. coli. The purified proteins were sent to a collaborating 
laboratory for further examination. 
 
Although several diagnostic polymerase chain reactions (PCRs) for Leishmania 
species causing human leishmaniasis are published, none of them is able to detect 
all different species and distinguish among them at the same time. Therefore, a 
diagnostic PCR was developed using the mini-exon gene (encoding the spliced 
leader) as template. A restriction fragment length polymorphism (RFLP) scheme was 
elaborated in order to identify different Leishmania species causing human 
leishmaniasis. The PCR and RFLP scheme is now in routine use at the STI. 
 
In order to identify potential virulence factors, vaccine candidates and drug targets of 
Leishmania infantum, two cDNA subtractions were performed: 
 (1) A none-infective L. infantum strain was subtracted from a highly infective strain. 
Several genes which were higher or exclusively expressed in the infective strain were 
identified. However, association with virulence could not be shown, since the two 
strains differed not only in virulence but also in growth rate. 
(2) Non-infective early promastigote stages were subtracted from late promastigote 
stages (metacyclic transmission stage) of the same strain. Several genes showing 
differential expression were selected including genes encoding nutrient transporters, 
cytochrome b5 and unknown proteins. One of them was the previously described 
metacyclic specific gene MAT-1. Three of the genes were recombinantly expressed 
in E. coli in order to perform immunization and preliminary localization studies. 
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1. Introduction 
 
Three different projects were combined within this PhD work: 
• Identification of suitable antigens for an early diagnosis system of canine 
leishmaniasis. 
• Development of a diagnostic PCR for human leishmaniasis. 
• Identification of potential virulence factors, vaccine candidates and drug 
targets of Leishmania infantum. 
 
1.1. On the biology of Leishmania 
1.1.1 Taxonomy 
 
Euglenozoa 
 Flagellated protists 
Kinetoplastidae  
Kinetoplastidae contain a single mitochondrion of respectable size. Its genome 
consists of a huge network of maxi and mini circles (the kinetoplast), where 
RNA editing was first described (Benne et al., 1986). The kinetoplast is 
associated with the flagellar root. 
Trypanosomatidae 
Trypanosomatidae are diploid organism, most of them are obligate parasites. 
Prominent members are Trypanosoma brucei brucei (sleeping sickness) and 
T. cruzii (Chagas disease). T. brucei is the only trypanosomatid, where sexual 
recombination was described (reviewed by Gibson and Stevens, 1999). 
Therefore, clonal distribution is believed to be the rule for all other species.  
Leishmania 
The genus Leishmania contains dozens of species, all of which are obligate 
parasites. They are transmitted by the bite of sandflys of the genus 
Phlebotomus (Old World) and Lutzomyia (New World). Vector stages are 
flagellated (promastigotes) and live extracellularly within the insect gut, 
whereas host stages do not posses a flagellum (amastigotes) and multiply 
intracellularly within phagolysosomes of phagocytes.  
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1.1.2 The Leishmania genome 
 
Leishmania sp. are diploid organisms, containing a genome of extraordinary 
plasticity: gene amplification under drug pressure yielding in extra chromosomal 
plasmids and mini-chromosomes was reported for L. tropica (Olmo et al., 1995).  
The Leishmania genome is very GC rich (63%), relatively small (approximately 34 
Mb), lacks substantial repetitive DNA, and is distributed among 36 chromosomes 
pairs ranging in size from 0.3 Mb to 2.5 Mb containing about 8’000 predicted genes 
(Myler et al., 1999).  
Most of the genes are transcribed polycistronic (reviewed by Campbell et al., 2003). 
The mRNA capping is done by trans-splicing: a capped mini-exon, the spliced leader, 
is spliced within the polycistronic primary transcript yielding in capped mRNAs 
containing at the 5’ end the 39 bases long mini-exon. The mini-exon gene itself is 
found in tandem repeats (head to tail) at about 200 copies per genome. This kind of 
trans-splicing is believed to display a primary capping mechanism (Ullu et al., 1996). 
Due to the polycistronic transcription, gene expression is believed to be controlled at 
post-transcriptional level (reviewed by Clayton, 2002). 
The 28S rRNA in trypanosomatids is cleaved into two larger 
(α, β) and several smaller subunits. On total RNA gels 
therefore 3 prominent ribosomal bands are visible, instead of 
two as in most other organisms (figure 1).   
 
A  
 
1.1.3. Life Cycle 
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PM has begun and small amounts of blood are visible in the hindgut (figure 2). 
Members of the Viannia subgenus (containing the species L. brasiliensis, L. 
guyanensis, L. panamensis and L. peruviensis) are distinguished by the fact, that 
they do not enter the hindgut. 
 
 
 
 
Figure 2: different parasite stages and locations within the course of 
a Leishmania infection in the sandfly vector (modified from Sacks 
and Kamhawi, 2001). 
 
 
 
The parasites escape to the anterior portion of the midgut, and attach with their 
flagellum to microvilli of epithelial cells. The attachment prevents the parasites to be 
excreted together with the digested blood meal at ~day 7 after feeding. The binding is 
mediated by the nectanomad’s lipophosphoglycans (LPG, a 
glycosylphosphatidylinositol-anchored polysaccharide) covering the whole surface of 
the parasites.  
Since LPG differs not only during life cycle (McConville et al., 1992), but also among 
Leishmania species, their attachment is not successful in each vector species. This 
leads to the fact, that the distribution of Leishmania species is restricted to the 
geographic distribution of a susceptible vector (table 1). It has also been shown, that 
Leishmania infections develop normal in the “wrong” vector, but are excreted within 
the digested blood meal (Hindle, 1931). Recently, a homologue protein of galactin (a 
galactose-binding protein found on mammal cells) has been suggested as interaction 
partner of LPG (Clayton, Swiss Trypanosomatid Meeting, Leysin, 2004). 
Next, nectanomads transform into haptomonads and metacyclics. By changing their 
LPG, they are released from the microvilli. Haptomonads cover the insect’s 
stomodeal valve and excrete a visceous gel like matrix, which restrict their motility. 
They also excrete a chitinase which partially destroys the valve. The damaged valve 
is no longer able to close properly during blood meal which facilitates the 
transmission of infective metacyclic parasites to the vertebrate host (Schlein et al., 
1992).  
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In the host’s blood, they are phagocytized by ‘professional’ phagocytes (neutrophils, 
monocytes and macrophages). The transformation of metacylics to amastigotes 
completes the life cycle. 
 
Table 1: The clinical manifestation, geographic distribution and vector usage of different Leishmania 
species (modified from Sacks and Kamhawi, 2001). 
Parasite Clinical 
forms 
Geographic distribution Proven or suspected 
vector 
L. donovani AVL, PKDL China 
India, Nepal, Bangladesh 
East Afrika 
P. alexandri 
P. argentipes 
P. martini, P. orientalis 
L. infantum 
 
 
L. chagasi 
ZVL, ZCL Southern Europe 
Eastern Mediterranean 
China 
Central and South America 
P. ariasi, P. perniciosus 
P. perniciosus, P. langeroni 
P. chinesis P. major 
Lu. longipalis 
L. major ZCL Middle East 
South West Asia 
Africa 
P. papatasi 
P. papatasi 
P. papatasi, P. duboscqi 
L. tropica ACL Middle East 
South West Asia 
Africa 
P. sergenti 
P. sergenti  
P. sergenti, P. saevus 
L. aethiopica CL, MCL, DCL East Africa P. longipedes, P. pedifer 
L. mexicana ZCL, DCL Central America Lu. olmeca 
L. amazonensis ZCL, DCL Central and South America Lu. flaviscutellata 
L. braziliensins CL, MCL Central and South America Lu. wellcomei, Lu. carrerai 
L. guyanensis CL Central and South America Lu. umbratilis, Lu. anduzei 
L. panamensis CL Central and South America Lu. trapidoi 
AVL: anthroponotic visceral leishmaniasis 
PKDL: post kala-azar dermal leishmaniasis 
ZVL: zoonotic visceral leishmaniasis 
ZCL: zoonotic cutaneous leishmaniasis 
ACL: anthroponotic cutaneous leishmaniasis 
MCL: mucocutaneous leishmaniasis 
DCL: diffuse cutaneous leishmaniasis 
 
 
1.1.4. Immunology 
 
In order to survive in the vertebrate host, Leishmania parasites use several immune 
evasion strategies: the most prominent is intracellular replication, which hides the 
parasites by the surrounding host cell from direct contact to the immune system. 
Many tactics of the parasites most probably are not yet known, however a few of the 
known strategies are listed in table 2. While these selected strategies are by far not 
all, the table shows the ability of the parasite to modulate the immune response at 
many different levels, from complement resistance to triggering the type of immune 
response towards higher susceptibility of the host. The latter tactic has great impact: 
a common rule is, that a TH1 type cytokine milieu yields in clearing of the parasite 
load, whereas a TH2 type cytokine milieu leads to susceptibility of the host (reviewed 
by Alexander et al., 1999; Launois et al., 1998). This makes sense, because TH1 
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cytokines are able to activate macrophages, which is the major killing mechanism of 
Leishmania parasites. TH2 cells induce a humoral response, which has little effect for 
clearance of intracellular parasites. By down regulating a protective TH1 response, 
the parasite therefore succeeds a dramatic intervention. 
Nevertheless, antibodies against several Leishmania antigens are present in the 
blood of both, asymptomatic and symptomatic hosts. 
 
Complement 
Metacyclic parasites resist complement mediated lysis by inactivation of complement 
factors and shedding of the membrane attack complex (MAC,  Brittingham et al., 
1995; Hermoso et al., 1991; Puentes et al., 1990). 
 
Natural killer cells (NK) 
Mice deficient in NK were shown to be only modestly less capable of eliminating L. 
donovani infection than control mice; and there was no difference seen in the course 
of L. major infections (Kirkpatrick and Farrell, 1982; Kirkpatrick and Farrell, 1984). It 
therefore appears that NK are, if at all, only involved in the response to visceral 
leishmaniasis. Here, it has been shown in vitro that L. donovani parasites interact 
with γ/δ+ human peripheral blood T cells and induce susceptibility to NK cell-
mediated lysis (Saha et al., 1999). 
 
Humoral response 
While anti-leishmanial antibodies have been shown to lyse promastigotes in vitro in 
the presence of complement, there is little evidence for a role in vivo: when 
antibodies are mixed in large quantities with the parasites before infection, the 
infectivity of promastigotes was reduced; however, when injected separately, there 
was no effect on disease development (Anderson et al., 1983). It therefore appears 
that a humoral response has no central role in clearing the parasite load. 
 
Cytotoxic T-cells (CTL, CD8+ T cells) 
CTL have traditionally been associated with resistance to viral infections, but they 
may also have an important role in immunity to intracellular microbes like 
mycobacterium (Chiplunkar et al., 1986). This may be due to direct cytotoxicity or 
through cytokine production and subsequent macrophage activation (some CD8+ T 
cells produce interferon γ (INF-γ) as well tumor necrosis factor α (TNF-α), see 
below). However, it is unclear, whether CD8+ T cells play a major role in the control of 
leishmaniasis. Since amastigotes multiply within phagolysosomes, presentation of 
processed Leishmania peptides is mostly restricted to MHC class II molecules. 
Nevertheless, some parasite proteins might be transported to the cytoplasm, from 
where they could be loaded to MHC class I molecules, thus allowing activation of 
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CD8+ T cells. 
 
CD4+ T cells 
There are two subsets of CD4+ T cells: TH1 cells, which provide a cytokine milieu 
inducing a cellular immune response, and TH2 cells, which help to establish a 
humoral response. Naïve CD4+ T cells differentiate into TH1 cells by activation in the 
presence of interleukin (IL) 12 and IFN-γ, whereas differentiation into TH2 cells 
occurs by activation in the presence of IL-4. The parasite’s ability to repress the IL-12 
gene (Carrera et al., 1996), therefore blocks the establishment of a protective TH1 
response. Most probably there are also other parasite and host factors involved in 
this process. 
TH1 type cytokines such as IFN-γ can activate macrophages in the presence of co-
stimuli, in contrast to the inhibitory effects observed by TH2 some cytokines. 
 
Activated Macrophages 
INF-γ (e.g. secreted by a TH1 cell that recognizes a foreign peptide bound to a 
macrophage’s MHC class II molecule) can activate macrophages. However, INF-γ 
alone is not capable of inducing leishmaniacidal activity (reviewed by Liew and 
O'Donnell, 1993). Auto- and parakrine acting co-stimuli (such as TNF-α) synergizing 
with INF-γ are needed here fore. 
The antimicrobial activity is achieved by nitric oxide (NO·, produced by the inducible 
NO synthase iNOS) and superoxide anion (·O2-) radicals. Being toxic by itself, it is 
unclear whether NO· is the final effector mechanism or if other molecules inflict final 
damage to Leishmania parasites. NO· can rapidly react with ·O2- to form the stable 
peroxynirtite anion ONOO- (Beckman et al., 1990). Once protonated, as it seems 
likely to occur in the acidic phagolysosomes, ONOO- decays rapidly into the stable 
radical nitric dioxide anion (NO2·-), and the highly reactive hydroxyl radical ·OH. 
Hydroxyl radicals react with almost all molecules found in living cells (at rate 
constants of between 109 and 1010 M-1s-1, Anbar and Neta, 1967). However, defense 
mechanisms of the parasites are able to inhibit iNOS expression (Balestieri et al., 
2002), MHC-protein synthesis, peptide loading and expression of co-stimulatory 
molecules (De Souza Leao et al., 1995; Reiner et al., 1987) and to detoxify ·O2- 
(superoxide dismutase). 
Cytokines secreted by TH2 cells such as IL-10 inhibit the expression of iNOS. 
Therefore, a TH2 response leads to susceptibility of the host. As discussed by Rittig 
and Bogdan (2000), there is weak evidence that some parasites are found in the host 
cell’s cytosol. These parasites could therefore escape macrophage activation by 
CD4+ T cells: Leishmania derived peptides could no longer be presented on MHC 
class II, but on MHC class I molecules, which would allow killing of the host cell by 
CD8+ T cells. However, Moore and Matlashewski (1994) showed that Leishmania 
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parasites are able to block apoptosis of the host cell. Nevertheless, only metacyclics 
(non-dividing parasites) have been seen within the cytosol, either by electron 
microscopy (harsh template preparation might result in rupture of phagolysosomes) 
or by video microscopy (too low resolution for visualizing membranes). 
 
Dendritic cells (DC) 
These ‘professional’ antigen presenting cells play a crucial role in the establishment 
of an immune answer, due to their ability to stimulate T lymphocytes (in addition to 
MHC molecules they express co-stimulatory signals to naïve T cells). Therefore, they 
represent key factors for the TH1/TH2 switch (Reid et al., 2000). Furthermore, they 
are capable to transport live parasites to lymph nodes (Ghosh and Bandyopadhyay, 
2003). Only DCs are able to induce a vigorous T-cell immune response to L. major in 
vitro in the absence of exogenous antigen (Moll et al., 1995). Thus, their role in the 
immune response to Leishmania cannot be overestimated. 
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Table 2: Selected immune evasion strategies of Leishmania (modified from Zambrano-Villa et al., 
2002) 
Evasion strategy Result References 
Inactivation of complement 
factors and shedding of the 
MAC complex  
Resists complement Brittingham et al. (1995) 
Hermoso et al. (1991) 
Puentes et al. (1990) 
Inhibition of the 
macrophages’ NOS 
Inhibits the oxidative burst Balestieri et al. (2002) 
Inhibition of MHC-protein 
synthesis, peptide loading 
and expression of co-
stimulatory molecules 
Reduces macrophage 
antigen presenting ability  
Reiner et al. (1987) 
De Souza Leao et al. 
(1995) 
Prevention of apoptosis of 
infected cells 
Extends the life-span of 
infected macrophages 
Moore and Matlashewski 
(1994) 
Repression of the IL-12 
gene 
Blocks the protective Th1 
response 
Carrera et al. (1996) 
IL-12: interleukin 12 
MAC: membrane attack complex 
MHC: major histocompatibility complex 
NOS: nitric oxide synthase 
 
1.1.5. Leishmaniasis 
 
The disease 
Leishmaniasis (briefly reviewed by Herwaldt, 1999) is endemic in areas of the tropic, 
subtropic and southern Europe and from rural to periurban areas.  The clinical 
manifestation ranges from cutanous and mucocutanous leishmaniasis (replication of 
the parasite within macrophages located in the dermis, and naso-oropharyngeal 
mucosa, respectively) to visceral leishmaniasis (replication of the parasite within the 
bone marrow, spleen or liver). Both, cutaneous and visceral leishmaniasis, are seen 
in a broad range of severity and manifestations. 
Cutaneous leishmaniasis is manifested as skin lesions, whereas visceral 
leishmaniasis (also known as kala-azar) is associated with fever, hepato-
splenomegaly, anaemia and many more life threatening symptoms. Post kala-azar 
dermal leishmaniasis, a syndrome that develops at variable times after resolution of 
kala-azar, is manifested by skin lesions and can be associated with relapse of 
visceral leishmaniasis. People suffering from this disease serve as reservoir hosts. 
Some forms of leishmaniasis represent zoonotic disease (as L .infantum), whereas 
others represent anthroponotic disease (as L. donovani). Infection of different 
species results in different symptoms (table 1). However, in immunosuppressed 
patients, the disease may develop unusual manifestations (as example the patient 
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described by Angarano et al., 1998). In 1990, VL was the fourth most common 
opportunistic parasitic disease in HIV-positive individuals in Spain after 
pneumocystosis, toxoplasmosis, and cryptosporidiosis (Montalban et al., 1990).  
 
Diagnosis 
There are many tools for diagnosis of leishmaniasis, each differing in sensitivity, 
specificity and cost intensity (reviewed by Guerin et al., 2002; Singh and Sivakumar, 
2003): 
• Detection of parasites, either directly by microscopy (low sensitivity) or after 
cultivation in vitro and in vivo (time consuming). 
• Serology: IFATs and ELISAs using pro- and amastigotes (better specificity) as 
antigens have been successfully evaluated; however antigen production is 
cost intensive. Several recombinant parasite proteins have been tested as 
antigens in ELISAs and direct agglutination tests. Recombinant K39 (a 
parasite homologue of kinesin) showed best results, and is commercially 
available for diagnosis of VL. While sensitivity and specificity appears to be 
lower than when using whole parasites as antigens, the cheap production 
costs represent a great advantage. 
• PCR using ribosomal genes, repetitive DNA elements, kDNA or other 
repetitive genes have been successfully used with good sensitivity and 
specificity.  
Since parasites are not equally distributed within the host’s body, detection of 
parasites by microscopy (with or without cultivation) or by PCR is dependent on 
biopsies, which can be painful and dangerous for VL patients. However, in 
immunosuppressed individuals, parasites are found with relatively high frequency 
within the blood, thus facilitating the diagnosis by PCR. 
 
Treatment 
Yet obtainable drugs and drugs in stages of testing are reviewed by Berman, (2003), 
Croft and Coombs (2003), Rosenthal and Marty (2003). Both, VL and CL is 
traditionally treated with pentavalent antimonials over a time course of 20-40 days, 
yielding in adverse reaction of these toxic compounds, especially in the presence of 
HIV co-infections. Antimonial resistance has strongly arisen in some areas in India, 
where VL is endemic (Sundar, 2001). There are alternative drugs such as 
Amphotericin B (need for intravenous infusion), Pentamidine (increasing treatment 
failures in India) and Miltefosine (the only oral antileishmanial agent available so far). 
Adverse reactions caused by all these drugs, high treatment costs (lowest for 
Miltefosine) and increasing drug resistance demand the development of new drugs, 
some of which are in the pipeline. However, in respect to drug resistance, there 
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cannot be enough alternative drugs. 
 
Vaccines 
At present, there is no vaccine in routine use; however, several are in different stages 
of testing (reviewed by Ghosh and Bandyopadhyay, 2003). It is crucial for a 
successful vaccine, that a protective TH1 type immune answer is induced (either by 
the adjuvant or by the vaccine itself). 
• Live vaccines  
In the age of genetically engineering, a practice used for centuries might have 
to potential for a come back: ‘leishmanization’. People were inoculated with 
live L. major at an aesthetically acceptable site resulting in live long protection 
from CL caused by L. major and L. tropica (Modabber, 1989; Nadim et al., 
1983). A major draw back of leishmanization was the high risk of complication 
and the development of a lesion and a scar after healing at the site of 
inoculation. This problem might be overcome by using genetically altered 
parasites. Two approaches have already successfully been performed: 
introduction of suicidal cassettes (Titus et al., 1995) and/or markers which are 
responsive to external signals for their destruction (Sah et al., 2002; Yan et al., 
2001). Another problem when using a live Leishmania vaccine, are the high 
production costs. Whether leishmanization works also for VL has not yet been 
shown. Here, development of a clinical episode would be fatal. 
• Killed vaccines 
Killed promastigotes have been used for CL with different success: while there 
was no protection in Iran, there were promising results in Ecuador and Brazil. 
• Recombinant antigens 
The first tested antigen was GP63 and showed promising results in the animal 
model, whereas responses of human T-cells were variable. The leishmanial 
elongation initiation factor (LeiF) is considered to be a promising vaccine 
candidate due to its ability to induce TH1 cytokines in humans, as well as the 
Leishmania homologue of the receptor for activated C kinase (LACK, in 
particular when IL-12 is used as adjuvant). 
• Synthetic peptides 
Several peptides have been successfully used in the animal model, such as 
peptides derived from GP63.  
• DNA vaccines 
Various naked DNA vaccines have been tested in animal models yielding in 
promising results, such as the glucose regulated protein, a member of the 
70kDa heat-shock protein family. 
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However, in most experimental systems, adjuvants are essential to induce protective 
immunity. Unfortunately, the most effective adjuvants generally cause strong 
inflammation, which may be needed for adjanticity, but may exclude their use in 
humans due to unacceptable side effects. This problem might be overcome when 
using dendritic cell vaccination (Moll, 2003). 
 
 
1.2. Basic molecular biological methods used during the 
PhD project 
 
Most of the routine methods were performed after the standard protocols described 
by Sambrook and Russel (2001).  
 
1.2.1. RNA  
Isolation 
RNA was either harvested according to the classical method of Chomczynski and 
Sacchi (1987) or using TRIZOL (Invitrogen) reagent. For long term storage, RNA was 
stored as a precipitate at -20°C, otherwise, RNA was dissolved in TE (10mM Tris·Cl 
pH 8, 0.5mM EDTA) and stored at -80°C.  
Northern blots 
Northern blots were performed using either formaldehyde, or preferentially 
glyoxal/DMSO as denaturating agents. For highly expressed genes, such as 
histones, even non-denaturating agarose gels worked very well (figure 3). 
PEG purified (refer appendix 6.A4) dsDNA probes 
were 32P-labeled using the High Prime Kit (Roche) 
and α32P-dCTP and hybridized overnight at 42°C. 
Beside Ultrahyb (Ambion), the two different 
hybridization buffers described in appendix 6.A1 
were successfully used.  
Reverse Transcription 
Three different derivates from Moloney Murine Leuke
successfully used: although unmodified M-MLV exhibi
showed to be the better choice for obtaining spliced le
Superscript II (Invitrogen). Superscript II is M-MLV con
acids responsible for RNase H activity. Unfortunately, t
 Figure 3: Northern blot of 
histone H2A using a non-
denaturating agarose gel.  mia Virus (M-MLV) RT were 
ts a weak RNase H activity, it 
ader (SL) cDNA compared to 
taining a deletion of the amino 
he deletion not only eliminates 
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the RNase H activity, but also lowers the reverse transcriptase activity. Best results 
were achieved when using an RT where the RNase H activity was destroyed by a 
single point mutation, as in M-MLV, RNase H- (Finnzymes). RNase A and H digestion 
after reverse transcription substantially increased the yield of a subsequent PCR. 
The protocol for reverse transcription and PCR amplification of SL cDNA is shown in 
appendix 6.A2. 
 
1.2.2. DNA 
Minipreps 
Minipreps were performed according to the alkaline lysis method. If plasmids were 
harvested from nuclease rich E. coli strains (as expression strains like BL21, 
Stratagene), a phenol extraction was performed prior to ethanol precipitation, and 
otherwise this step was omitted.  
Isolation of genomic DNA 
Parasite DNA (from patients and in vitro cultures) was isolated using SDS mediated 
cell lysis, proteinase K digestion, phenol extraction and ethanol precipitation 
(appendix 6.A3). 
PCR 
PCR was performed using Taq DNA polymerase. If blunt ended PCR products were 
required, a proportion of 8:1 Taq:Pfu in Taq buffer was used. Since the Leishmania 
genome is very GC rich, addition of DMSO (2-12%) was often necessary. Other 
melting-point reducing agents like betaine or glycerol did not show beneficial effects. 
For amplification of difficult templates, the concentration of PCR additives like 
Tween20 (0.1-1%) and BSA (0.1-1g/l) had to be optimized.  
Purification of PCR products 
PCR products were purified using phenol extraction and ethanol precipitation. If small 
fragments, such as primers or restriction fragments had to be removed (as prior to 
ligation or sequencing), a polyethylene glycol (PEG) precipitation was performed 
(appendix 6.A4). Gel purification was avoided due to its low yield. 
Sequencing 
Sequencing was done using Perkin Elmer’s DNA sequencing kit according to the 
manufacturer’s protocol. Due to the high GC content of the intron and non-
transcribed spacer sequencing of the mini-exon gene showed to be difficult. The high 
GC content might yield in a stable secondary structure of the intron (since its 
secondary structure is required for trans-splicing). Addition of DMSO could not 
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improve the quality of the sequences, in contrast to cloning the PCR fragments prior 
to sequencing, and the adaptation of the sequencing procedure described in 
appendix 6.A5. 
Sequencing of large inserts was done as shown appendix 6.A6: the plasmids were 
cut with polylinker restriction enzymes, which also cut within the inserts. After 
religation and retransformation, the obtained minipreps contained deletions. 
Therefore, it was possible to sequence large insert by solely using vector primers and 
without purchasing an erase a base kit. Theoretically it would be possible to 
sequence directly after religation, but this simplification was not tested. 
Ligation 
Ligations were performed using either T/A cloning kit (Promega), cycle restriction 
ligation (appendix 6.A7) or Quick DNA ligase (New Egland Biolabs). 
E. coli Transformation  
Electro-poration: since input and harvest is not very profitable using large scale 
preparation of electro-competent cells, a fast small scale approach was used 
(appendix 6.A8). 
Chemo-transformation: this was the method of choice, if many transformations had to 
be performed with the same E. coli strain. The Inoue method (appendix 6.A9) was 
used to prepare chemo-competent cells resulting in 108 to 109 colonies/µg 
supercoiled pUC18 DNA. The advantages compared to electroporations were: many 
more aliquots of competent cells after large scale production, ligation mixes could 
directly be transformed without the need of purification and many samples could be 
transformed at the same time with less handling. 
 
1.2.3. Proteins 
Expression 
Most of the proteins were expressed as glutathione-S transferase (GST) fusion 
proteins. However, none of them was in the soluble fraction. Neither lowering the 
IPTG concentration for induction, nor the temperature for protein expression, nor 
adding ethanol for chaperon induction, nor combining all variations could change this 
feature.  
For expression of genes selected during the cDNA subtraction, a modified pGEX 
(GST fusion) vector was used (appendix 6.A10). 
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Purification 
Recombinant proteins containing a His-tag were preliminary purified as inclusion 
bodies (appendix 6.A11). Since renaturation did not work for any protein, the 
inclusion bodies were subsequently purified using Ni-NTA agarose (Qiagen) under 
denaturing conditions. If the protein was badly soluble in urea, 8M urea was replaced 
with 6M guanidine chloride in all solutions. 
Recombinant MAT-1 was affinity purified under mild denaturing conditions using 
sarkosyl and glutathion sepharose (appendix 6.A12). 
Immunofluorescence assays (IFAs) 
Parasite cultures were spun, resuspended in fetal calf serum (FCS) and spread on 
glass slides. After drying, the slides were fixed for 10min at -20°C using acetone 
alone or 1:1 methanol:acetone. The slides were partitioned using a hydrophobic pen 
allowing the use of only 10µl of serum or secondary antibody. 
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2. Development of an early diagnosis test 
system for canine leishmaniasis caused by  
L. infantum 
 
 
2.1. Background 
 
In Southwest Europe, HIV and L. infantum co-infections are an emerging concern for 
public health (see table 3). Although cases of co-infection have so far been reported 
in 33 countries worldwide, most of the cases have been notified in south-western 
Europe (France, Italy, Portugal and Spain). The cases reported in these countries 
between January 1996 and June 1998 represent 49.8% of the total number of cases 
(1440) reported since 1990 (http://www.who.int/emc-
documents/leishmaniasis/docs/wholeish200042.pdf). 
 
Table 3: Leishmania/HIV co-infections, total number of reported cases. 
Years Spain France Italy Portugal
1990-98 835 259 229 117 
1996-98 412 132 85 88 
 
The usual clinical features of VL such as fever, weight loss, and swelling of the liver, 
spleen and lymph nodes, are not always present or may be hidden by other 
associated opportunistic infections with similar symptoms. However, most of the co-
infected patients who participated in a WHO study (84.9%) showed the usual clinical 
features (table 4, http://www.who.int/emc-
documents/leishmaniasis/docs/wholeish200042.pdf). 
 
Table 4: clinical manifestations in Leishmania-HIV co-infected patients  
participating in a WHO study (1990-98). 
Clinical features Number % 
Visceral – typical 
Visceral – atypical 
Cutaneous 
Others 
Mucocutaneous 
Mixed 
736 
82 
36 
6 
4 
3 
84.89 
9.46 
4.15 
0.69 
0.46 
0.35 
Total 867  
 
In the Mediterranean, dogs represent the main reservoir of this parasite (see 
references in chapter 2.3). Therefore, control of human leishmaniasis must not 
exclude control of canine leishmanisis: reduction of prevalence in the reservoir is 
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expected to lower the transmission rate to humans. However, due to the increasing 
number of infected humans, parasitized human hosts may also contribute 
substantially to the transmission. In order to control canine leishmaniasis, an early 
diagnosis system is needed because dogs are capable to transmit the parasite, 
before showing any symptoms of the disease.  
For mass use (in the Mediterranean, there are many street dogs), diagnosis by PCR 
or microscopy is not feasible. Existing serological tests for canine leishmaniasis are 
not able to detect parasites within early stages of the disease. Furthermore, some 
reliable diagnostic methods (such as IFAT based on whole parasite antigens) cannot 
be used in masses, due their high production costs. Thus, a cheap serological test 
capable of diagnosis of early canine leishmaniasis is needed. In order to identify 
antigens suitable for such a diagnostic tool, we screened L. infantum cDNA 
expression libraries. These would be cheaply produced as recombinant proteins, 
which then could be used as antigens for Western blots, ELISAs or direct 
agglutination tests.  
 
 
2.2. Methods 
 
In order to identify antigens suitable for diagnostic use, several cDNA expression 
libraries were constructed and screened with sera of L. infantum infected dogs. 
Preliminary, Clontech’s Capfinder Kit was used combined with SMART λ phages. 
(The capfinder method uses the feature of certain reverse transcriptases to add 
several G’s at the 3’ end of the cDNA when reverse transcribing capped mRNAs in 
the presence of Mn2+ ions. This allows adaptor ligation and subsequently PCR 
amplification of full length cDNA.) However, beside that the cDNA obtained after PCR 
looked strange (a smear on the gel, from bottom to top), no λ clone reacted with dog 
sera of L. infantum infected dogs. The simplest explanations for this finding were, that 
expression in E. coli failed due to presence of stop codons and absence of ribosome 
binding sites (RBS) within the 5’ UTR of the cloned cDNAs: in prokaryotes, a defined 
sequence (the RBS) has to be located within a distinct distance from the ATG for 
proper translation. Since most of the Leishmania full length cDNA apparently lacked 
the RBS, the obtained cDNA library was not suitable for a serum screen. 
Therefore, both cDNA amplification and vector were changed.  We used the spliced 
leader as primer binding site instead of the CAP finder adaptor. Furthermore, the 
amplified cDNA was restriction digested and non-directionally ligated into λgt11 DNA 
containing 3 different adaptors (appendix 6.A10), resulting in 6 frame expression of 
all cDNA fragments as lacZ fusion proteins. 
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2.3. Identification of recombinant antigens from Leishmania 
infantum suitable as early diagnostic tool 
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Abstract 
 
Early diagnosis of canine leishmanaiasis caused by the protozoan parasite 
Leishmania infantum remains an important requirement for the control of the 
disease. In order to identify antigens suitable for such an early immunological 
diagnosis system we generated a phage lambda cDNA expression library and 
this was screened using sera from naturally and artificially infected dogs. With 
this approach we selected 8 antigens which strongly reacted with naturally 
infected dog sera. Subsequent sequencing identified these as histones, 
ribosomal proteins, and a mitochondrial protein. Upon generation of 
recombinant protein Western blot analysis was performed to assess the 
specificity and reactivity of the identified antigens with sera of infected and 
healthy control dogs. Three of these antigens were further selected for the 
development of a dipstick test. 
  23.1 
 Introduction 
 
Domestic dogs represent the main reservoir of Leishmania infantum (Old 
World) and L. chagasi (New World) and therefore play a key role in the 
transmission of the disease to humans. A way to control the disease would be 
to treat dogs found infected with Leishmania rapidly. However, dogs showing 
already symptoms might have been transmitting for an extended period [1, 2] 
and therefore a diagnostic assay is need that quickly can determine infectivity 
in subpatently infected dogs. Although usually transmitted by the bite of an 
infected sandfly vector, direct dog to dog transmission [3] and blood 
transfusion routes [4] have been reported. 
Because the metacyclic stage of Leishmania parasites is responsible for the 
transmission from the insect vector to the vertebrate host and the 
establishment of a new infection, this stage is the first to be seen by the host’s 
immune system. Once phagocytised by macrophages, metacyclic stages 
develop into amastigotes and multiply within phagolysosomes. In order to 
identify antigens suitable for an early diagnostic test, a cDNA expression 
library of L. infantum metacylic stages was generated and screened with a 
serum pool from L. infantum positive dogs. 
Most of the mRNAs in trypanosomatids contain a conserved 5’ sequence, the 
spliced leader [5]. And we exploited this feature to PCR amplify the cDNA 
obtained after reverse transcription of total RNA using spliced leader 
sequence specific primers. In order to construct an expression library, the 
PCR products were restriction digested and ligated into a λ phage which was 
previously modified with adaptors in three reading frames. Since the cDNA 
was not directionally cloned into the phage vector, all 6 frames of the PCR 
fragments were expressed in this λ library. 
Screening the λ library we identified several fragments of histones, of 
ribosomal proteins, and a mitochondrial protein. In order to perform Western 
blot analysis using sera of artificially and naturally infected dogs, some of the 
identified antigens were sub-cloned in expression plasmids and expressed in 
E. coli, though we failed to express two of the gene fragments. However, 
Western blot results of the other clones were promising, in particular those 
obtained with clones representing epitops within the histones H2A and H4. 
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 Materials and methods 
 
Parasite culture 
Promastigotes of the L. infantum strain LEM 768-A/ST were cultivated in vitro 
at 27°C in a 1:1 mixture of SDM-79 [6] and Schneider’s medium [7] containing 
15% [v/v] heat inactivated fetal calf serum. 10ml cultures were inoculated at a 
density of 106 parasites/ml and harvested 14 days later. 
 
cDNA preparation 
After washing the parasites in phosphate buffered saline (PBS), total RNA 
was extracted after the method of Chomczynski and Sacchi [8] using 0.5ml 
guanidinium thiocyanate solution per ml in vitro culture. Approximately 2µg 
RNA were reverse transcribed with 200 U Moloney Murine Leukemia Virus 
(M-MLV) reverse transcriptase (Invitrogen) using the primer 5’-
CGACTGTACGTGAATTCGC(T)20 (all oligonucleotides were manufactured by 
Invitrogen). Prior to PCR, RNA was removed by RNase A (Boehringer) 
digestion and cDNA was PCR amplified using the primer above and the 
spliced leader primer 5’-
AACTAACGCTATATAAGTATCAGTTTCTGTACTTTATTG. Taq DNA 
polymerase (Invitrogen) was added in presence of 10% dimethyl sulfoxide 
(DMSO) and the amplification was done under the following conditions: 25 
cycles 30sec 94°C, 30sec 54°C, 2min 72°C. The PCR products (figure 1A) 
were NlaIII (all restriction enzymes obtained from New England Biolabs) 
digested and purified by phenol extraction, and precipitated with ethanol and 
polyethylene glycol (PEG)[9]. 
 
Lambda expression libraries 
Three different adaptors to provide three reading frames were ligated with T4 
DNA ligase (New England Biolabs) to EcoRI cut and dephosphorylated λ-gt11 
DNA (Amersham). All adaptors contained phosphorylated 5’ EcoRI 
overhangs, 3’ NlaIII overhangs and 6x His tags. The adaptor in frame 1 was 
made with the two oligos 5’-P-AATTCCACCATCACCATCACCACCATG and 
5’-GTGATGGTGATGGTGG, frame 2 was made with 5’-P-
AATTCCACCATCACCATCACCATGCATG and 5’-
CATGGTGATGGTGATGGTGG, and frame 3 was made with 5’-P-
AATTCCACCATCACCATCACCACATG and 5’-P-
TGGTGATGGTGATGGTGG. After the ligation, the remaining free adaptors 
were removed by PEG precipitation and the NlaIII digested cDNA was ligated 
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 into the λ-gt11 DNA using T4 DNA ligase. The phages were packed with the 
Gigapack® III Gold Packaging Extract (Stratagene). The library was amplified 
in Y1090r- E. coli strain (Stratagene) after the protocol of Sambrook and 
Russel [10]. 
 
Screening of libraries 
The libraries were screened with a serum pool of L. infantum positive dogs 
(kindly by Felix Grimm, University of Zürich) after the protocol of Sambrook et 
al. [11]. Briefly, the phages were plated at a density of 104 plaque forming 
units on 30ml Petri dishes and incubated for 4 hours at 42°C. The plates were 
overlaid with nitrocellulose sheets (Hybond N, Amersham) which were 
previously saturated in 10mM isopropyl-β-D-1-thiogalactopyranoside (IPTG). 
The plates were incubated for another 6 hours at 37°C. The sheets were 
removed afterwards and blocked with PBS containing 5% not fat milk powder. 
A serum pool from L. infantum-positive dogs was pre-adsorbed with crude E. 
coli extract and the antibody screen was conducted with 1:500 diluted sera. 
After 2 h, sheets were washed and incubated in a 1:2000 dilution of an 
alkaline phosphatase labeled goat anti-dog IgG antibody (Southern). Unbound 
antibody was washed away and recognized clones were visualized by a 
BCIP/NBT color reaction (Blotting substrates, BioRad). Areas of positive 
clones were identified on the master plates, phages were re-plated at a lower 
density, and screened again with the same serum pool in order to isolate 
single clones. Specificity of the recognition was assessed using a serum pool 
of uninfected control dogs (kindly by Felix Grimm, University of Zürich). Single 
clones which were negative with control sera but positive with sera from 
infected dogs were PCR amplified directly from the plagues. PCR was 
performed to amplify the inserts using the λgt11-primers 5’-
GGTGGCGACGACTCCTGGAGCC and 5’-
GACACCAGACCAACTGGTAATG, and the PCR products were directly 
sequenced on an ABI automated sequencer. 
 
Subcloning in expression plasmids 
The PCR products were either cloned into pQE32 containing a 6x His tag 
(Qiagen) or into the glutathion-S-transferase (GST) fusion vector pGEX-1 
(Amersham). Prior to ligation into the pQE vector, PCR products of λ clones 
were NlaIII digested, their ends polished using Pfu DNA polymerase 
(Promega), and purified by phenol extraction with subsequent ethanol and 
PEG precipitation. Fragments were then cycle restriction ligated [12] using 
SmaI and T4 DNA ligase. For the ligation into the pGEX vector, PCR products 
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 and vector were EcoRI cut and the vector was dephosphorylated using calf 
intestinal alkaline phosphatase (Promega). Before ligation with T4 ligase, both 
vector and insert were purified by phenol extraction and subsequently 
precipitated with ethanol and PEG. pQE clones were expressed in M15 cells 
(Qiagen) and pGEX clones in BL21 cells (Amersham).  
 
Expression in E. coli 
Expression clones were grown in Luria-Bertani medium (LB) at 37°C until the 
optical density reached 0.8 and protein expression was induced with 0.5mM 
IPTG for 4 hours at 37°C. All proteins were found in inclusion bodies. 
Because pGEX inserts still contained the λ adaptors, proteins expressed from  
pQE and pGEX both contained 6 x His tags and were purified with Ni-NTA 
Agarose (Qiagen) under denaturing conditions. 
 
Western Blots 
Recombinant proteins were run on Tricine-SDS polyacrylamide gels [13] 
manufactured by Bio-Rad (Ready Gel Tris-Tricine Gel, 10–20%). Heat shock 
protein 70 [14] (HSP-70, kindly obtained from C. Jaffe), and the identified 
ribosomal protein (RP) L7 and RP-L10 were on the same gel, as well as the 
selected proteins histone (HIS) H4, HIS-H2A and RP-L7a (figure 1B). After 
electrophoresis, proteins were transferred onto nitrocellulose membranes. 
After blocking with 5 % milk powder in TNT (10 mM Tris/HCl pH 8, 150mM 
NaCl, 0.05% Tween 20) over night at 4°C, blots were incubated for 3 hours at 
room temperature with a 1:500 dilution (TNT, 1% milk powder) of positive 
serum pool or a 1:200 dilution of single serum samples. An alkaline 
phosphatase labeled goat anti-dog IgG at 1:5000 (TNT, 0.1% milk powder) 
was used as a secondary antibody. Blots were revealed with BCIP/NBT 
blotting substrate (Bio-Rad). 
 
 
 
Results and Discussion 
 
The development of an early diagnostic assay for canine leishmaniasis would 
be a major step forward in the control of the disease which is transmitted by 
sand flies from infected dogs. Few assays are currently being tested either 
based on the detection of specific DNA or on the detection of antibodies 
against certain antigens elicited early during the infection. In order to identify 
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 additional antigens useful for the development of an early antigen based 
assay, we created a cDNA expression library and screened it with sera from 
dogs naturally infected with L. infantum. 
 
Spliced leader cDNA 
For the synthesis of cDNA we made use of the fact that all transcribed 
messengers in the trypanosomidae contain a spliced leader sequence, which 
increased the yield of specific transcripts. The size distribution of the amplified 
spliced leader cDNA that we used for construction of the λ libraries is shown 
in figure 1A. Size distribution of eukaryotic mRNA usually ranges from 0.5 to 
many kb with most of the mRNA between 2 and 3kb. The spliced leader 
cDNA we prepared showed an acceptable distribution with a slight under-
representation of mRNAs longer than 3kb, but still representing a large 
fraction of the metacyclic parasite’s transcriptome, which was screened with 
dog sera. 
 
Serum screen 
With the screen using sera from Leishmania infected dogs we identified 
fragments of the following genes: histone (HIS) H2A, histone H3, and histone 
H4. Furthermore, we identified the ribosomal proteins (RP) L7 (2 fragments), 
L7a, L10, and the mitochondrial 2-oxoglutarate carrier. It seems to be 
surprising that no surface proteins have been identified, but only highly 
expressed cytoplasmatic, nuclear, or mitochondrial proteins. One might 
speculate that because most of the metacyclic stages are killed immediately 
after transmission [15] into the mammalian host, and because the amastigote 
stages are intracellular, the antibody response might be mostly induced by 
antigens descending from lysed parasites. Therefore one might indeed expect 
antibodies against common and immunogenic antigens regardless of their 
cellular localization. Nevertheless, protection against cutanous leishmaniasis 
in vervet monkeys using recombinant HIS-H1 [16] and immunity in mice 
against visceral leishmaniasis using DNA encoding for the ribosomal protein 
P0 as vaccines [17] has been reported. The positive effects of both 
immunizations most probably were derived from cell-mediated immunity.   
 
Recombinant proteins 
The selected epitopes of HIS-H2a, H4 and one of the two epitops of RP-L7 
were successfully expressed as GST fusion proteins. The ribosomal proteins 
RP-L7a and L10 were expressed in the pQE system. However, sub cloning of 
HIS-H3 and one epitope of RP-L7 failed. Furthermore, no visible amount of 
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 protein was obtained after induction of the mitochondrial 2-oxoglutarate carrier 
expression. All other proteins were expressed at high levels and found in 
inclusion bodies. These antigens were tested in 4 artificially infected dogs, 
from which sera were collected 60, 120, 180 and 330 days post infection 
(table 1). HSP-70 showed best results: all sera recognized this antigen 60 
days post infection. Also the histones H2A and H4 showed good results, in 
contrast to the ribosomal proteins. Although only one strain of L. infantum was 
used to infect the dogs, the results seemed to be transferable to naturally 
infected dogs: here, HSP-70 and the two histones were recognized very well, 
in contrast to the ribosomal proteins. 5 of the western blots are shown in 
figure 1B. However, the starting point of the infection is unknown in naturally 
infected dogs. 
 
Conclusions 
In Leishmania diagnosis, a battery of tools exists [18] including PCR, ELISA, 
IFAT, dipstick or agglutination tests, but there are no gold standards. 
Therefore, the development of a diagnostic tool of high sensitivity, specificity 
and of low costs remains of high priority. 
Different methods for detection of L.infantum have been compared [19]. PCR, 
ELISA and a dipstick (Leishmania RAPITEST), both based on recombinant 
K39 protein [20] were tested. The serological tests were more sensitive than 
PCR, suggesting that serology should preferently be used as method for 
diagnosis, also because of the lower costs and easier implementation. 
IFAT using amastigotes as antigen showed great sensitivity and specificity 
[21]. However, high production costs contradict its application in the field. 
Therefore, a diagnostic test based on dipstick, agglutination or ELISA 
technology using 2 or more different recombinantly expressed epitopes of L. 
infantum proteins might be the best solution. Leishmania possesses high 
variability in HIS-H2A [22] and H4 genes [23]. A diagnostic test using solely 
histones as antigens therefore might fail to detect all L. infantum strains. 
Nevertheless, the two selected histones and HSP-70 showed promising 
results in all of our experiments, in contrast to the ribosomal proteins L7, L7a 
and L10. However, one epitope of RP L7 was not expressed recombinantely 
during this work as well as HIS-H3, which could show similar results as HIS-
H2A and H4. Further, the mitochondrial oxoglutarat carrier should not be 
forgotten only because protein production failed in this attempt. 
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Table1: recognition of recombinant antigens by sera of artificially infected dogs (A-D, F) and 
control dog (E) respectively. 
Gene HIS-H2A HIS-H4 RP L7 RP L7a RP L10 HSP-70 
Expression vector pGEX pGEX pGEX pQE pQE  
A 1201) 120 -2) - - 60 
B 120 120 - - - 60 
C 120 120 - - 120 60 
D 60 120 - - 60 60 
E (control) - - - - - - 
F 120 120 - - - 60 
1) days post infection 
2) no recognition at all 
 
 
 
 
 
 
Figure 1: A: Size distribution of the spliced leader cDNA used for constructing the expression 
library (M: size marker, SL: spliced leader cDNA). B: Western blots using sera of naturally 
infected dogs (1-5) and uninfected control dog (0) respectively. 
 
  23.10 
2.4. Discussion 
 
We identified several potential antigens suitable for a diagnostic test. However, much 
more data are needed concerning their value to recognize early infections of different 
L. infantum strains responsible for HIV-Leishmania co-infections. Ongoing studies 
currently address these issues. 
Several core histones were selected in the serum screen. Here the questions arise: 
why are the histones from the genus Leishmania highly diverse and immunogenic? 
What are the advantages for the parasites? So far, they have not been satisfactory 
answered. Nevertheless, the unusual properties of Leishmania histones might 
represent a key factor in leishmaniasis. 
It remains questionable whether a diagnostic test, even when sensitive and specific, 
would improve the control of leishmaniasis. It would need a huge effort (personnel 
and cost intensive) to test and treat the majority of the canine population in Southern 
Europe. From this point of view, a cheap vaccine would be favorable: a vaccine might 
be allocated as lures (like in Switzerland for control of rabies), and there would be no 
need for diagnosing and treating infected animals, which most probably would also 
lead to treatment failures and selecting drug resistance in parasite strains. However, 
since no such vaccine is available yet against any parasitic disease, any other 
possible step has to be kept in mind. 
In Brazil, there has been a study on the impact of using insecticide impregnated dog 
collars, which yielded satisfactory effects (Reithinger and Davies, 2002). However, 
this handling prevents only dogs with owners from infective sandfly bites. For street 
dogs, a similar approach would be to use masses of insecticides which surely has a 
great impact on environment and most probably also on public health. 
Mass diagnosis and treatment of street dogs still appears to be a possible approach 
at present. However, it does not seem to be an elegant way to control leishmaniasis, 
especially in regard to drug resistance. Furthermore, chemotherapy of canine 
leishmaniasis is tagged by high relapse rates (Baneth and Shaw, 2002). 
Nevertheless, an early diagnostic test surely would be a useful tool for veterinarian 
purpose. 
 24
3. Development of a PCR assay for diagnosis of 
human leishmaniasis and differentiation of 
Leishmania species 
 
 
3.1. Background and method 
 
There are many different approaches for diagnosing human leishmaniasis (reviewed 
by Guerin et al., 2002; Singh and Sivakumar, 2003): direct detection of the parasite 
by microscopy (low sensitivity), or cultivation (time consuming and not all strains are 
equally grown in vitro and in vivo), PCR and serological methods. In Europe, most of 
the leishmaniasis cases represent HIV co-infections. A recent study compared 
several different tools for diagnosis of leishmaniasis in HIV patients (Deniau et al., 
2003). In respect to sensitivity and specifity, the results suggest the use of a 
combination of PCR and cultivation.  
Although several diagnostic PCRs for Leishmania species are published (reviewed 
by Wilson, 1995), none of them is able to detect all different species and distinguish 
among them at the same time. Either these PCRs amplify DNA of all species but 
cannot distinguish between them (as PCRs amplifying ribosomal genes), or they are 
only capable to amplify DNA deriving from a limited number of species (as PCRs 
amplifying kinetoplast DNA). 
We have chosen the mini-exon gene as PCR template, because this gene is 
abundant in about 200 copies per genome of each Leishmania species (sensitivity) 
and shows enough polymorphism for distinguishing the different species. It consists 
of the highly conserved mini-exon, a semi conserved intron and a highly variable non 
transcribed spacer, resulting in length and sequence polymorphism of the PCR 
product, which allows differentiation of Leishmania species using restriction length 
polymorphism. 
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3.2. Diagnostic genotyping of Old and New World 
Leishmania species by PCR-RFLP 
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Abstract
We have designed a new genotyping scheme for molecular diagnosis of the different Leishmania species pathogenic to humans. This
scheme is based on PCR amplified sequences from the gene for the spliced leader RNA (mini-exon). This target was selected because it
is present as tandem repeats (100 to 200 copies) in the genus Leishmania and other kinetoplastida, but is absent from the mammalian hosts
and the sandfly vectors. The exon is highly conserved, whereas the intron and non-transcribed spacer region vary in size and sequence among
different species. Thus, it was possible to amplify DNA from both Old and New World pathogenic Leishmania complexes using a single
pair of primers deriving from the conserved region of the mini-exon tandem repeat. Species identification was performed by digesting
mini-exon PCR products with one or two different restriction enzymes. Restriction fragment length polymorphism (RFLP) generated
species-specific patterns of bands visualized in agarose gels, which allowed to differentiate each species unequivocally. © 2003 Elsevier
Science Inc. All rights reserved.
1. Introduction
Leishmaniasis is a parasitic disease which is associated
with a wide spectrum of clinical manifestations depending
on the species of the parasite, the host’s immune response
and the saliva of the sandfly vector (Grimaldi and Tesh,
1993; Gradoni and Gramiccia, 1994). The variety of symp-
toms range from self-curing ulcerative or diffuse, non-ul-
cerative cutaneous lesions, to persistent and often disfigur-
ing mucocutaneous lesions or the potentially fatal visceral
form of the disease. The assignment of the parasite species
based alone on geographic location or the site of infection is
not satisfactory. Accordingly, correct diagnosis and classi-
fication of a pathogenic Leishmania isolate is essential to
determine the clinical prognosis and a species-specific ther-
apeutic approach (Navin et al., 1992; Berman, 1997; Ro-
mero et al., 2001). In addition, epidemiologic studies as
well as the usage of reference strains in laboratory experi-
ments greatly depend on correct species-identification.
The genus Leishmania is divided into the two subgenera
Viannia and Leishmania according to their development in
the sandfly vector. Specification within the subgenera de-
pends on several factors such as the geographical distribu-
tion of an isolate, the clinical presentation of the disease,
and the epidemiology of the vector and the animal reservoir
(Lainson and Shaw, 1987; Pearson et al., 2001). Since
morphologic differentiation of Leishmania species is not
possible, a variety of biochemical, immunologic, or molec-
ular criteria were introduced for classification of pathogenic
species, such as characterization by isoenzyme electro-
phoresis (zymodeme analysis) (Kreutzer and Christensen,
1980), by monoclonal antibodies (serodeme) (Grimaldi et
al., 1987) or by hybridization with species-specific probes
such as minicircle DNA probes (Wirth et al., 1989).
With the advent of the PCR technology, several PCR-
based assays for species differentiation were developed. As
targets for amplification served either nuclear DNA, such as
the SSU rRNA gene (van Eys et al., 1992), repetitive se-
quences (Piarroux et al., 1995), internal transcribed spacer
(ITS) regions (Cupolillo et al., 1995, Eisenberger and Jaffe,
1999), the tubulin gene (Luis et al., 1998), the gp63 gene
locus (Victoir et al., 1998), microsatellite DNA (Russell et
al., 1999), or extrachromosomal DNA, such as the repetitive
kinetoplast DNA (kDNA) minicircles (de Bruijn and
Barker, 1992; Belli et al., 1998).
While all these different approaches offer a multitude of
valid taxonomic characters for species identification, a sim-
ple assay (one single PCR) which is also comprehensive (all
Leishmania species) as well as reliable and applicable in the
routine diagnostic laboratory, has been missing to date.
* Corresponding author. Tel.: 41-61-284-81-17; fax: 41-61-271-
86-54.
E-mail address: ingrid.felger@unibas.ch (I. Felger).
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Most molecular diagnostic methods developed for genotyp-
ing Leishmania species were based on the polymorphic
kDNA minicircle, which is considered a prime candidate for
a sensitive assay because of the presence of 10000 to 20000
minicircles per cell. In a first attempt to device a genotyping
assay comprising all Leishmania species pathogenic to hu-
mans, we performed a sequence analysis of kDNA which
revealed too great an amount of sequence variation between
kDNAs of different New and Old World species, thus im-
peding the design of universal primers. An alternative
kDNA approach based on multiplex PCR has been devel-
oped (Belli et al., 1998). However, the yield of amplifica-
tion products is generally compromised in multiplex PCR
by primer dimer formation resulting in a loss of sensitivity
of the assay.
Therefore, we chose the mini-exon (or spliced leader
(SL)) gene found in all kinetoplastida as target sequence for
a genotyping assay. The mini-exon gene, which is involved
in the trans-splicing process in kintoplastid protozoa, is
present 100 to 200 times per nuclear genome as tandemly
repeated copies, and it is absent from the vertebrate host or
invertebrate vector. A detailed study on sequence variation
in the mini-exon gene repeat of human pathogenic Leish-
mania species had previously shown that the diversity de-
tected in the non-transcribed spacers represents an informa-
tive phylogenetic marker (Fernandes et al., 1994).
These features, together with a species-specific diversity,
which conforms roughly with the species boundaries within
the genus, designate the mini-exon for being exploited as a
genotyping marker. We have used a PCR approach similar
to that of Fernandes et al. (1994), but combined it with
restriction digests of the PCR product, a method which is
routinely used for other genotyping tasks (Singh, 1997). The
resulting patterns of restriction fragments were characteris-
tic for each species. Thus, we achieve a high resolution and
high discrimination power, while the assay is still based on
a single PCR reaction with universal primers.
2. Materials and methods
2.1. Parasite strains
The strains representative for the different Leishmania
species, which were used in this study are listed in Table 1.
In addition, 35 isolates from patients attending the poly-
clinic of the Swiss Tropical Institute (STI) were genotyped.
2.2. In vitro cultivation of Leishmania
The promastigote forms were cultivated at 27°C without
gas phase in a 1:1 mixture of Schneider’s modified Dro-
sophila medium (SDM-79) (Brun and Scho¨nenberger,
1979) and Schneider’s medium (SM) (Cunningham, 1977)
complemented with 15% heat-inactivated fetal bovine se-
rum. Leishmania from a 5-day-old culture were harvested
and counted with the Cell Counter and Analyser System
CASY® 1 (Scha¨rfe System GmbH, Reutlingen, FRG). The
cells were washed twice with 0.15 M phosphate-buffered
saline (PBS) pH 7.4, pelleted by centrifugation, resus-
pended in the appropriate buffer depending on further ex-
periments, and processed immediately.
2.3. DNA preparation
Cultured cells, corresponding to about 2  108 cells,
were transferred into 500 l digestion buffer (10 mM Tris/
HCl pH 8; 5 mM EDTA; 0.5% SDS). Proteinase K (Sigma-
Aldrich, Inc., CH) was added to a final concentration of 0.5
mg/ml and the sample was incubated over night at 56°C.
DNA was extracted successively with one volume of phenol
pH 8.0, one volume of phenol/chloroform, and one volume
of chloroform according to standard procedures (Sambrook
and Russell, 2001). DNA was precipitated from the aqueous
phase with ethanol, the pellet washed with 75% ethanol, air
dried and finally resuspended in 100 l H2Odest.
2.4. PCR
The location of the forward primer Fme (5-TAT TGG
TAT GCG AAA CTT CCG-3) and reverse primer Rme
(5-ACA GAA ACT GAT ACT TAT ATA GCG-3) within
Table 1
Parasite strains
Species International code Source
L. aethiopica MHOM/ET/72/L100 2
L. amazonensis MPRO/BR/72/M1845 1
L. braziliensis MHOM/PE/85/LEM772 2
L. chagasi MHOM/BR/74/PP75 1
L. colombiensis IGOM/PA/85/E582.34 1
L. donovani MHOM/IN/80/DD8 2
L. donovani MHOM/CN/0000/WangJie1 1
L. donovani MHOM/KE/1967/MRC(L)3 1
L. donovani IMAR/KE/1962/LRC-L57 1
L. donovani MHOM/SD/1982/Gilani 1
L. donovani MHOM/ET/0000/Hussen 1
L. guyanensis MHOM/GF/99/LEM3713 3
L. guyanensis MHOM/GF/2000/LEM3952 3
L. infantum MHOM/FR/78/LEM75 2
L. killicki MHOM/TN/80/LEM163 1
L. major MHOM/IL/85/LEM769 2
L. mexicana MNYC/BZ/62/M379 1
L. naiffi MDAS/BR/79/M5533 1
L. panamensis MHOM/PA/71/LS94 1
L. peruviana MHOM/PE/84/LC39 1
L. tropica MHOM/SU/74/K27 2
L. venezuelensis MHOM/VE/74/PM-H3 1
The parasites were provided by:
1 The WHO Leishmania Reference Strain Collection at the London
School of Hygiene and Tropical Medicine (LSHTM), London, UK.
2 Prof. Dr. Reto Brun from the Laboratory of Protozoology at the Swiss
Tropical Institute in Basel, CH.
3 Dr. Renaud Piarroux, Laboratoire de Parasitologie-Mycologie, Hopital
Jean Minjoz, Universite´ de France-Comte´, Besancon, F.
116 J. Marfurt et al. / Diagnostic Microbiology and Infectious Disease 46 (2003) 115–124
the mini-exon gene repeat is shown in Fig. 1. Two l of
DNA solution were amplified in a 100 l reaction contain-
ing 50 mM KCl, 20 mM Tris-HCl pH 8. 4 (GIBCO™,
Invitrogen™ Life Technologies, CH), 0.2 mM dNTPs (Am-
ersham Biosciences Europe, CH), 12% DMSO (Fluka
Chemika, CH), 40 mM tetramethylammonium chloride
(Carl Roth GmbH, FRG), 1. 5 mM MgCl2 (GIBCO™), 0.5
M of each primer (MWG Biotech AG, CH), and 1 U Taq
polymerase (GIBCO™). The PCR conditions were 5 min at
94°C followed by 25 to 35 cycles of 30 sec at 94°C, 30 sec
at 54°C, and 45 sec at 72°C. The number of cycles depended
on the origin and concentration of the template. PCR prod-
ucts were separated on a 1.5% agarose gel.
2.5. Sensitivity titration assays
A) Crude Leishmania extracts: To test whether samples
can be directly used in the PCR assay, cultured cells were
resuspended in PBS pH 7. 4 and tenfold serial dilutions of
5  106 to 2. 5  102 cells per millilitre (ml) were prepared,
yielding a concentration range from 10000 to 0.5 parasites
per 2 l. The dilutions were subjected to three freeze-thaw
cycles, incubated at 95°C for 10 min and 2 l of the
solutions were directly used in the PCR reaction.
B) Purified Leishmania DNA: DNA concentrations were
determined by measuring the optical density (OD) at 260
nm with a GeneQuant® RNA/DNA Calculator (Amersham
Biosciences Europe GmbH, CH). Tenfold serial dilutions of
0.15 mg to 1. 5 pg per ml were prepared, yielding a con-
centration range from 300 ng to 3 fg per 2 l which were
used in the PCR assay.
2.6. Specificity assays
The specificity of the mini-exon PCR assay was deter-
mined by testing different concentrations of purified DNA
from the human host and other pathogens in the assay.
Human DNA was extracted from peripheral blood mono-
nuclear cells (PBMCs) from a volunteer as described in
section 3. Genomic DNA from Mycobacterium spp. (i.e., M.
tuberculosis and M. ulcerans) and Plasmodium falciparum
was kindly provided by the STI laboratories of Molecular
Immunology and Molecular Parasitology, respectively. Cul-
tured organisms from other kinetoplastida (i.e., Crithidia
spp. and Trypanosoma spp.) were kindly provided by the
laboratory of Protozoology at STI. DNA was extracted and
purified as described in section 3.
2.7. Restriction digests
Ten l of the PCR products were digested with 1U Eae
I (New England Biolabs®, Inc., USA) and at least one
additional enzyme according to the genotyping scheme
(Fig. 2). The restriction enzymes and the corresponding
reaction buffers and conditions are summarized in Table 2.
Resulting restriction fragments were separated on a 2. 5%
agarose or 10% polyacrylamide gel. Fragment sizes were
estimated by comparison with bands of a DNA length stan-
dard (1 kb ladder DNA size marker, GIBCO™). In cases of
uncertainty, restriction fragments of a given strain were run
in parallel with digested PCR products of known culture
strains.
2.8. Sequencing of the mini-exon gene
PCR products were purified by size-selective polyethyl-
eneglycol (PEG) precipitation (Lis, 1980). Briefly: the PCR
reaction was mixed with 1. 5 volumes of a 20% PEG
solution in 1 M NaCl in a microtube and incubated for 10
min at room temperature. The tube was centrifuged for 20
min at 14000 g in a microfuge. The precipitated PCR
Fig. 1. The mini-exon repeat of Leishmania. Each repeat contains a highly conserved exon (39 bp), a moderately variable transcribed intron region (55 to
101 bp), and a highly variable non-transcribed spacer sequence (51 to 341 bp). Location of primer sites (Fme and Rme) are indicated with arrows.
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products were washed with 1 volume of 75% ethanol (cen-
trifugation for 5 min at 14000 g), air dried and resus-
pended in 15 l H2Odest. The PCR products were cloned by
TA cloning (Zhou et al., 1995) using the pGEM®-T Vector
System (Promega, Madison, USA) according to the manu-
facturer’s instructions. Bacterial colonies harboring plas-
mids containing the mini-exon genes were identified by
PCR screening with vector primers SP6 (5-ATT TAG GTG
ACA CTA TAG-3) and T7 (5-TAA TAC GAC TCA CTA
TAG GG-3) using the same PCR conditions as described
Fig. 2. The mini-exon PCR-RFLP genotyping scheme. GenBank accession numbers are given in brackets. Vertical arrows denote the consecutive processing
of the samples; horizontal, dashed arrows denote the expected fragment sizes (bp) of the given restriction enzyme digest. n, undetermined nucleotides in the
sequence; RFLP, confirmed by RFLP analysis; *, mini-exon sequences from the subgenus Viannia lack an Eae I restriction site.
Table 2
Restriction enzymes, buffers and reaction conditions used for RFLP analysis
Enzyme* Source Recognition site Reaction buffer* Reaction
conditions
Eae Ia Enterobacter aerogenes 5-PyGGCCPu-3 NEB 1 1 h at 37°C
Eco72 Ib Escherichia coli 5-CACGTG-3 Y/Tango™ 1 h at 37°C
Hae IIIa Haemophilus aegypticus 5-GGCC-3 NEB 2 1 h at 37°C
Mbo Ia Moraxella bovis 5-GATC-3 NEB 3 1 h at 37°C
Mlu Ia Micrococcus luteus 5-ACGCGT-3 NEB 3 1 h at 37°C
Nco Ia Nocardia corallina 5-CCATGG-3 NEB 4 1 h at 37°C
Not Ia Nocardia otitidis-cavarium 5-GCGGCCGC-3 NEB 3  BSA 1 h at 37°C
Rsa Ia Rhodopseudomonas sphaeroides 5-GTAC-3 NEB 1 1 h at 37°C
Sma Ia Stenotrophomonas maltophilia 5-CCCGGG-3 NEB 4 1 h at 25°C
* Enzymes and ready-to-use buffers were purchased from:
a New England Biolabs (NEB), BioConcept Laboratories, CH,
b MBI Fermentas GmbH, Labforce AG, CH.
118 J. Marfurt et al. / Diagnostic Microbiology and Infectious Disease 46 (2003) 115–124
above. The CONCERT™ Rapid Plasmid Miniprep System
(GIBCO™, Invitrogen™ Life Technologies, CH) was used
to purify the plasmid DNA. 100-200 ng of the purified
plasmid DNA was used for the sequencing reaction which
was performed using the ABI PRISM™ Dye Terminator
Cycle Sequencing Ready Reaction Kit (Applied Bio-
sciences, CH) based on the dideoxy termination method
(Sanger et al., 1977). Mini-exons were sequenced twice in
both directions using vector primers SP6 and T7 and PCR
primers Fme and Rme. Cycle sequencing (25 cycles of 96°C
for 30 sec, 50°C for 15 sec, and 60°C for 4 min) was
performed in a GeneAmp PCR System 2400 (Perkin Elmer)
and sequences were analyzed using the ABI PRISM™ 310
Genetic Analyzer (Perkin Elmer) and the ABI PRISM™
software.
3. Results
3.1. The mini-exon PCR assay
To achieve highest PCR sensitivity and efficiency (high
yield of specific amplicons, no primer artifacts), conditions
were optimized by adding DMSO and tetramethylammo-
nium chloride to the reaction mix and determining the
optimal annealing temperature of 54°C in a Mastercycler®
gradient 5331 (Eppendorf, Hamburg, FRG). Amplification
products varied in size which was indicative of the different
Leishmania complexes. Fig. 3 shows a selection of mini-
exon PCR products of varying fragment sizes from different
Leishmania species. The smallest fragments of 223 to 226
bp were obtained by the New World species belonging to
the subgenusViannia (i.e., the complexes L. braziliensis
(Fig. 3, lane 7) and L. guyanensis (lane 8)), whereas those
belonging to the subgenus Leishmania produced longer
products, ranging from 283 to 327 bp (i.e., L. mexicana
complex (lanes 5 and 6)) or from 420 to 443 bp (New World
Leishmania species unassigned on complex level (not
shown in Fig. 3)). Old World species (i.e., the complexes
L. donovani (lane 2), L. major (lane 3), L. tropica (lane 4)
and L. aethiopica (not shown in Fig. 3)) gave rise to am-
plification products ranging from 378 to 435 bp. In one of
our L. donovani isolates, amplification of genomic DNA
produced three PCR fragments of slightly different sizes.
This finding was confirmed by a GenBank (EMBL) search
which also revealed three different mini-exon sequences
(Accession numbers: X69453, X69456, and X69443, re-
spectively). This suggested the presence of three mini-exon
repeats in L. donovani, detectable by PCR at least in one of
the L. donovani strains (MHOM/IN/80/DD8).
Sensitivity titration experiments were performed with
selected strains representing the size range of the expected
mini-exon PCR products. Whereas the assay detected 50
cells of the species L. infantum, L. major (Fig. 4), L. mexi-
cana and L. tropica, amplification products of L. brasilien-
sis and L. guyanensis were already detected with 10 para-
sites in the PCR reaction. Assuming that the DNA content
of Leishmania is approximately 100 fg per genome (Myler
and Stuart, 2000), the results obtained with crude extracts
corresponded well with those observed with purified DNA.
Fig. 3. PCR amplification products of different Leishmania species. Lanes:
M, 1 kb ladder DNA size marker; 1, Negative control (H2Odest); 2.
L. infantum (MHOM/FR/, 78/LEM75); 3, L. major (MHOM/IL/85/
LEM769); 4, L. tropica (MHOM/SU/74/K27); 5, L. amazonensis (MPRO/
BR/72/M1845); 6, L. mexicana (MNYC/BZ/62/M379); 7, L. braziliensis
(MHOM/PE/85/LEM772); 8, L. guyanensis (MHOM/GF/99/LEM3713);
9, L. guyanensis (MHOM/GF/2000/LEM3952).
Fig. 4. Sensitivity of the mini-exon PCR assay. Crude extracts from
cultured L. major organisms were tested in the PCR assay. Lanes: M, 1 kb
ladder DNA size marker; 1, 10,000 parasites (p); 2, 1000 p; 3, 500 p;
4, 100 p; 5, 50 p; 6, 10 p; 7, 5 p; 8, 1 p; 9, 0.5 p; 10, H2Odest.
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The detection limit was 3 pg DNA with the species yielding
amplification products larger than 250 bp, but reached
300 fg with those producing the smallest PCR fragments
(223 to 226 bp).
To assess the specificity of our PCR assay, we tested
DNA from the human host as well as from other pathogens
and related kinetoplastida in the PCR reaction. Whereas the
mini-exon sequences of Trypanosoma brucei rhodesiense,
T. b. gambiense and T. cruzi were not amplified with these
primers, the other kinetoplastida (i.e., Crithidia bombi,
C. lucilia and C. fasciculata) revealed PCR products be-
tween 400 and 430 bp in size. The PCR yield was lower
with Crithidia than with Leishmania species, indicating
mismatches between Crithidia mini-exon and our primer
sequences. However, Crithidia species were discernible by
the absence of an Eae I restriction site and the production of
a unique pattern of fragments (318 and 88 bp) with the Hae
III digest which was not found with any Leishmania species
(data not shown).
3.2. PCR-RFLP genotyping scheme
The observed size difference of PCR products identified
the different Leishmania complexes, but did not discrimi-
nate between individual species. Therefore, we chose to
subsequently digest the PCR products with restriction en-
zymes in order to produce a species-specific RFLP pattern
in an agarose gel. The resulting pattern of bands depends on
both, mutations in the recognition sequence of the chosen
restriction enzyme, and thus on the number of the fragments
generated, and on size variation of the internal non-tran-
scribed spacer fragment. In order to establish such a RFLP
genotyping scheme, we initially performed a GenBank
(EMBL) search. The diversity of the mini-exon genes
within the Leishmania and Viannia subgenus was deter-
mined by sequence alignments (ClustalW, BCM Search
Launcher, http://searchlauncher.bcm.tmc.edu/), and re-
striction enzymes differentiating between the individual
species were identified using the Webcutter version 2.0
program (http://www.firstmarket.com/firstmarket/cutter/
cut2.html). Using this information, restriction maps of
the mini-exon repeat of different Leishmania species
were produced. As a result, we defined different digests
which allowed species discrimination: Eae I proved to be
the most informative restriction enzyme, because it di-
gested all mini-exon PCR products of the Leishmania
subgenus in a species-specific manner, but it did not cut
the mini-exon of the species of the subgenusViannia. The
latter PCR products were digested with Hae III, Nco I, or
Rsa I which identified each species unequivocally.
Whereas the species belonging to all other complexes
were differentiated by a second round of restriction di-
gests as shown in the flow diagram in Fig. 2. This dia-
gram depicts the mini-exon RFLP genotyping scheme
and indicates the fragment sizes expected from the nu-
cleotide sequences submitted to GenBank. This virtual
sequence analysis suggested that all Leishmania species
can be distinguished by mini-exon PCR-RFLP.
3.3. Validation of the genotyping scheme with cultured
Leishmania reference strains
The genotyping scheme deduced from sequence infor-
mation from GenBank was validated with culture strains
representative for different species. Fig. 5 shows the RFLP
pattern of different species on an agarose gel after diagnos-
tic restriction digests with Eae I and Hae III. Two different
L. donovani strains (lane 1 and 2 of Fig. 5) produced
different RFLP patterns. This is in agreement with the fact
that 3 different mini-exon sequences of L. donovani have
been found in the GenBank search. The analyzed isolates
correspond to the restriction map of mini-exon sequence
accession numbers X69443 and X69453, respectively.
L. panamensis in lane 11 remains uncut by Hae III and
therefore reflects the PCR product. The 468 bp band reflects
occasional amplification of two consecutive mini-exon re-
peat units. This PCR artifact is due to the mini-exon’s
arrangement as tandem repeats and is more likely to occur
in small Viannia-type repeat units. The 403 bp band in lane
4 represents the PCR band of L. tropica which occurred due
to partial digest of the amplified DNA. The unexpected
215 bp fragment of L. mexicana in lane 8 might either be an
artifact due to partial digest (Eae I site at position 112), or
suggests the co-existence of two different mini-exon repeat
units within this species.
Next we examined whether this new genotyping scheme
based on GenBank sequences can be used to characterize
field isolates or applied in molecular epidemiologic studies.
23 isolates of L. infantum and 7 isolates of L. major (for-
merly typed by isoenzyme analysis) deriving from bone
marrow or skin biopsies of patients attending the polyclinic
of the STI were analyzed. All showed the expected restric-
tion pattern according to the genotyping scheme (results not
shown). In the course of genotyping Leishmania laboratory
strains representative for given species from different ori-
gins (see Table 1), we encountered several inconsistencies
between the observed RFLP pattern and the genotyping
scheme. These might well reflect existing problems in
Leishmania taxonomy. The L. chagasi strain (MHOM/BR/
74/PP75) used in our study could not be differentiated from
L. infantum (MHOM/FR/78/LEM75) since both strains pro-
duced identical RFLP patterns.
In some cases, the expected RFLP pattern based on
GenBank sequences could not be confirmed (i.e., for
L. aethiopica, L. infantum, L. mexicana, L. naiffi, and
L. panamensis). We therefore performed sequence analysis
of the mini-exon gene amplified from reference strains of
these species (Accession numbers: AY155501, AY155503,
AY155508, AY155505, and AY155509, respectively). Fig.
2 represents the final genotyping scheme, which is con-
firmed by RFLP and sequence data from laboratory strains
available to us (Mini-exon genes sequenced in our labora-
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tory appear underlined in Fig. 2). Additionally, mini-exon
genes from Leishmania strains whose sequences were
not available in GenBank (i.e., L. colombiensis, L. killicki,
L. peruviana, and L. venezuelensis), were sequenced (Ac-
cession numbers: AY155502, AY155504, AY155506, and
AY155507, respectively) in order to complete the initial
genotyping scheme.
4. Discussion
The present genotyping assay is based on amplification
of the mini-exon gene and was shown to be sensitive due to
the repetitive character of this template. An added technical
and cost-reducing advantage is the use of a single instead of
a nested PCR for the amplification of all Leishmania spe-
cies. Therefore, there is no need for multiplex PCR with
species-specific sets of primers which is likely to result in a
loss of sensitivity.
The detection limit was 50 parasites for Leishmania
species producing amplification products ranging from 300
to 450 bp, whereas the sensitivity for the species belonging
to the Viannia subgenus was 10 organisms. The enhanced
sensitivity in the latter subgenus can be attributed to the
smaller size (220 to 227 bp) and the higher copy number of
these mini-exon sequences. However, our assay does not
reach the sensitivity reported for the amplification of SSU
rRNA or kDNA (Meredith et al., 1993; Rodgers et al.,
1990), where detection limits from 1 to 10 parasites are
probably due to a hundredfold higher copy number of these
molecules per haploide Leishmania genome.
We have shown that the assay is specific to the Leish-
mania genus and correctly identifies species representing a
broad taxonomical and geographical diversity. There were
no products amplified with DNA from other microorgan-
isms which might show clinical manifestations similar to
those of leishmaniasis (e.g., Plasmodium spp. and Myco-
bacterium spp.). The test was also negative for the related
kinetoplastida Trypanosoma brucei gambiense, T. b. rhod-
esiense and T. cruzi. These are important features because
mixed infections of Leishmania and T. cruzi are known to
occur (Chiaramonte et al., 1996) and there are geographical
Fig. 5. RFLP patterns of different Leishmania species after restriction enzyme digest with Eae I and Hae III. Eae I digest: lanes 1 to 9; Hae III digest: lanes
10 to 12. Lanes: M, 1 kb ladder DNA size marker; 1, L. donovani (MHOM/CN/0000/Wang Jie1); 2, L. donovani (MHOM/IN/80/DD8); 3, L. infantum
(MHOM/FR/78/LEM75); 4, L. tropica (MHOM/SU/74/K27); 5, L. killicki (MHOM/TN/80/LEM163); 6, L. major (MHOM/IL/85/LEM769); 7, L. aethiopica
(MHOM/ET/72/L100); 8, L. mexicana (MNYC/BZ/62/M379); 9, L. amazonensis (MPRO/BR/72/M1845); 10, L. braziliensis (MHOM/PE/85/LEM772);
11, L. panamensis (MHOM/PA/71/LS94); 12, L. naiffi (MDAS/BR/79/M5533).
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regions where leishmaniasis and malaria or mycobacterial
infections co-exist. However, the assay generated PCR
products with DNA from the kinetoplastida Crithidia spp.
Though a contamination of the laboratory or a leishmanial
lesion is theoretically possible, the risk is low and Crithidia
spp. can be differentiated from Leishmania spp. by the
production of a characteristic RFLP pattern (Fig. 2). We
also demonstrated that no amplicons were produced with
human DNA (data not shown) and the sensitivity was not
compromised when PCR reactions were conducted with
crude Leishmania extracts. This is promising since the assay
could be directly applied to patient specimens. Thus, in vitro
cultivation of the parasite, which is limited in sensitivity
because of special growth requirements of certain species
and the risk of contamination (Berman, 1997), could be
avoided.
Two criteria are essential for a species-specific and sen-
sitive diagnostic test: 1) a repetitive target sequence for
PCR, since sensitivity increases with the copy number of the
amplified sequence, and 2) an adequate degree of polymor-
phism showing variation between species but not between
different isolates belonging to one species. With respect to
species differentiation, the mini-exon repeat proved to be an
ideal target for RFLP genotyping, because it shows a fair
but finite amount of sequence variation between individual
species. While the genotyping scheme, which was initially
based on sequences derived from the GenBank, could be
validated with most of the laboratory strains, we also en-
countered several inconsistencies, in particular in the dis-
crimination of closely related species. The WHO isolate of
L. chagasi showed the same RFLP genotype as L. infantum,
despite the fact that a distinct restriction pattern was ex-
pected according to the GenBank entry. This allows several
interpretations: 1) the reference culture and the isolate used
for sequencing were not the same species, 2) there was an
initial mix up of L. infantum and L. chagasi samples, 3)
L. chagasi is portrayed by two distinct genotypes, one of
which corresponds to that of L. infantum, 4) the mini-exon
genotypes do not segregate according to species boundaries,
and 5) both species are not only closely related but still can
recombine. This problem can only be resolved by analyzing
a number of different isolates of both species. However,
since there has already been some doubt about the distinct-
ness of these two species, the analysis with several molec-
ular methods suggest that L. chagasi might simply be
L. infantum imported into the New World (Mauricio et al.,
1999). In cases where many isolates of the same species
were available to us, such as 23 L. infantum strains from
patients, the predicted RFLP genotype was confirmed in 22
cases. In one case, a misclassification was found. The iso-
late, earlier characterized as L. donovani, was found to be
L. infantum. This was a plausible result, because the sample
has originally been isolated from Phlebotomus ariasi, a
vector typical for L. infantum.
The restriction maps derived from GenBank sequences
of L. aethiopica and L. mexicana could not be confirmed
with our reference strains. Therefore, the mini-exon genes
were sequenced in our laboratory and confirmed by PCR-
RFLP analysis. These differences in the sequences and thus
in the RFLP patterns may be due to: 1) intra-specific vari-
ability within the mini-exon gene, 2) the existence of two
different repeat units within a species such as in L. dono-
vani, or 3) sequencing errors in the GenBank sequence.
(The L. mexicana sequence (Accession number: X69447)
contained several undetermined nucleotides). Good quality
nucleotide sequences could not be obtained easily. Cloning
the PCR products instead of direct sequencing improved
results. The sequencing problem might be due to secondary
structures and the high GC content of this fragment. This is
also reflected by the fact that PCR amplification was opti-
mal at DMSO concentrations as high as 12%.
The mini-exons of the Old World species L. killicki and
the New World species L. colombiensis, L. peruviana and
L. venezuelensis were sequenced for the first time. Since the
RFLP pattern could be confirmed for all four species, they
are included in the genotyping scheme. It is worth mention-
ing, that the mini-exon sequences of L. venezuelensis and
L. major are very similar and are hardly distinguishable by
RFLP analysis. Recently, the close relationship of these two
species has also been revealed by molecular analysis of the
ITS region and the SSU rRNA gene (Berzunza-Cruz et al.,
2002). Alternatively, the L. venezuelensis reference strain
might simply represent a member of L. major-like strains
known to occur in several regions in the New World. Such
strains were characterized by isoenzyme and schizodeme
analysis in earlier studies and are believed to correspond to
L. major populations imported from the Old World into the
Americas (Momen et al., 1993; Yamasaki et al., 1994).
Though GenBank entries seemed to enable the discrim-
ination between the individual species within the L. bra-
ziliensis complex (i.e., L. b. braziliensis and L. b. peruviana)
and the L. guyanensis complex (i.e., L. g. guyanensis and
L. g. panamensis), our sequence analysis revealed that the
homology of the mini-exon genes within each of the two
complexes was very high and we failed to identify a differ-
entiating restriction site. Thus, sequencing was required to
discriminate between the single species within the L. bra-
ziliensis and the L. guyanensis complex. However, these
results were not surprising since the status of the individual
species within these two Leishmania complexes still re-
mains controversial (Banuls et al., 2002).
The few problems we encountered during this project
might well reflect common difficulties in Leishmania tax-
onomy. In part, they occurred because of ambiguities in
the starting material. Tracing the origin of samples and
confirming the identity, as well a misclassification or
even mislabelling of culture lines complicated the molec-
ular determination. This is also reflected in the mini-
exon sequences submitted to GenBank of which many re-
vealed inadequately defined sources and were incomplete.
A clearly identified set of reference DNAs or culture lines of
all clinically relevant Leishmania species would greatly
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assist in the establishment of a reliable and robust diagnostic
tool. These observations call for an inter-laboratory collab-
oration aiming at the establishment of a set of reference
samples for the unequivocal determination of each species
by all available techniques.
In conclusion, our PCR-RFLP based genotyping assay is
cheap, reliable with high sensitivity and specificity, easy to
perform, and enables differentiation of all the clinically
relevant Leishmania species within a reasonable time-
frame.
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We recently developed a new PCR-restriction fragment length polymorphism (RFLP)-based assay using the
miniexon sequence from the genus Leishmania. Here we report the application of this new genotyping method
to naturally infected clinical samples for the differentiation of New and Old World Leishmania species. Of the
newly developed assay and four currently applied diagnostic tests (i.e., in vitro cultivation, serology, and two
other molecular assays using either the small subunit-internal transcribed spacer sequence or a repetitive
genomic sequence), the miniexon assay showed the highest sensitivity, 89.7%, compared to 70.6, 57.1, 51.7, and
79.3%, respectively. Species differentiation was robust and reliable compared with that by two other Leishmania
genotyping techniques. The assay provides a valuable tool for the identification of Leishmania directly from
clinical samples and enables determination of the infecting species by a facile technique with high discrimi-
nation power. Since Leishmania causes a broad spectrum of diseases distinguished by different parasite and
host factors, detection and characterization of the infecting species is crucial for the confirmation of a
diagnosis as well as the establishment of the clinical prognosis and the initiation of an adequate therapeutic
approach. The miniexon PCR-RFLP assay will facilitate such determination and might improve diagnosis and
treatment of leishmaniasis.
Diagnosis of leishmaniasis can be made on the basis of
clinical and epidemiological data but has to be confirmed by
the demonstration of the parasite to avoid potential misdiag-
nosis (29). Because of differences among the Leishmania spe-
cies in levels of virulence and in responses to the various
chemotherapeutic regimens, correct identification is essential
in order to determine the clinical prognosis and prescribe an
appropriate species-specific therapeutic regimen (3).
At present, the classical methods used for the direct detec-
tion of the parasite include the visualization of amastigotes by
microscopic examination of Giemsa-stained smears and in
vitro culture of the parasite. Though microscopic examination
is rapid, cheap, and easy to perform, it lacks sensitivity due to
the generally low number of parasites in tissue samples (42).
Culture techniques are more sensitive but require a sophisti-
cated laboratory setup, are time-consuming, and harbor the
risk of contamination (3). Indirect methods based on the anal-
ysis of specific immune responses cannot distinguish between
past and current infections, and depending on the antigens
used in serological assays, diagnosis can be complicated by
cross-reaction of antibodies with other pathogens. Another
drawback is the limited sensitivity because antibody titers may
vary with the infecting species, tissue tropism, and the immu-
nocompetence of the host (1).
Species discrimination is important not only for epidemio-
logical reasons but also for clinical reasons. Leishmania species
were originally classified by their geographical distributions
and the clinical presentations of the diseases they cause, as well
as by epidemiology, sand fly vectors, or animal reservoirs (20).
Since morphological discrimination of Leishmania species is
not possible, a variety of biochemical, immunological, and mo-
lecular tools have been developed for the differentiation of
the pathogenic species, such as isoenzyme, serodeme, and
schizodeme analysis and hybridization techniques with spe-
cies-specific DNA probes (16, 43).
With the advances in molecular techniques, a number of
molecular markers and PCR protocols for the detection or
identification of Leishmania on different taxonomical levels
(genus, complex, and species) have been reported (11, 43).
Target sequences for characterization include either nuclear
DNA, such as the small subunit rRNA (SSU rRNA) gene (40),
a repetitive genomic sequence (30), the miniexon (spliced
leader) gene repeat (18), the beta-tubulin gene region (22), the
gp63 gene locus (41), and internal transcribed spacer (ITS)
regions (9); microsatellite DNA (36, 37); or kinetoplast DNA,
such as minicircle sequences (34).
While all the above-mentioned approaches provide a multi-
tude of valid taxonomic characters for differentiation, they are
accompanied by a number of factors which limit their use in a
routine diagnostic laboratory. Some of the assays are restricted
to the identification of Leishmania at the genus level (5, 25)
and do not allow species differentiation, whereas others are
adapted for individual complex characterization (10, 13), which
limits their applicability to restricted geographical areas. Other
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molecular approaches involve the combination of PCR ampli-
fication with DNA probe hybridization to enhance the sensi-
tivity of the assay (33, 35), an elaborate and time-consuming
procedure. The use of random amplified polymorphic DNA
analysis of genomic DNA (12, 38) is limited since it requires
purified parasite DNA and highly standardized PCR condi-
tions to guarantee specificity. In addition, the results may be
difficult to interpret. Assays based on the multiplex PCR tech-
nique (17) represent yet another approach but harbor the risk
of reduced sensitivity caused by primer dimer formation.
The miniexon gene of kinetoplastid protozoa, which is in-
volved in the transsplicing process of nuclear mRNA, is pres-
ent as 100 to 200 tandemly repeated copies per nuclear ge-
nome. Each repeat consists of three major parts: a transcribed
region comprising a highly conserved 39-nucleotide exon; a
moderately conserved intron, approximately 55 to 101 bp; and
a nontranscribed, intergenic spacer of variable length (51 to
1,350 bp) depending on the genus and species (39). These
features allow the miniexon to be utilized as a genotyping
marker. Based on these characteristics, we recently established
a PCR assay similar to that described by Fernandes et al. (14).
This PCR assay amplifies all the miniexon sequences in a single
reaction using universal primers, allowing preliminary discrim-
ination between the major complexes (i.e., Old World Leish-
mania, New World Leishmania, and New World Viannia com-
plexes) as a result of the variability in sizes of the amplification
products. After restriction enzyme digestion of the PCR prod-
uct, a characteristic restriction fragment length polymorphism
(RFLP) pattern is produced that depends on size variations in
the polymorphic spacer regions as well as mutations in the
recognition sites of a chosen restriction enzyme. The miniexon
PCR-RFLP genotyping scheme was validated with cultured
World Health Organization reference strains of Leishmania
and cultured isolates from patients attending the polyclinic of
the Swiss Tropical Institute (STI). It has proven to be a valu-
able tool showing high resolution, sensitivity, and an ability to
discriminate between all clinically relevant Leishmania species
(24).
The aim of this study was to optimize the miniexon PCR
assay for routine diagnosis of infections in naturally infected
clinical samples without the need for cultivation and to com-
pare our results with those obtained by using current methods
for diagnosis of leishmaniasis. Moreover, genotyping results of
the miniexon RFLP system were validated by parallel analysis
of the samples with two other PCR-RFLP typing schemes
which are based on an uncharacterized repetitive genomic
sequence of Old World Leishmania (30) or the ITS region of
the rRNA gene (37a).
MATERIALS AND METHODS
Clinical samples. A total of 50 samples from patients presumed to have
leishmaniasis were used in this study. The samples were either sent to our
diagnostic unit or obtained from patients returning from areas where the disease
is endemic who attended the STI polyclinic with either cutaneous signs or a
tentative diagnosis of visceral leishmaniasis. Three samples were from patients
with a concurrent HIV infection. The samples consisted of 25 skin biopsy spec-
imens, 16 bone marrow biopsy specimens, 2 lesion aspirates, 4 blood samples
(anticoagulated with EDTA), 2 duodenal biopsy specimens, and 1 gastric biopsy
specimen. Four of the 25 skin biopsy specimens arrived as paraffin-embedded
tissue samples. Samples were split on arrival; one part was used for in vitro
cultivation, except in the case of paraffin-embedded tissue samples, and the other
part was processed for PCR analysis. Corresponding serum samples were avail-
able from 16 patients, and they were tested for Leishmania-specific antibodies by
an indirect fluorescent-antibody test (IFAT). Of these, four samples were de-
rived from patients who had traveled to the Americas, six samples were derived
from patients for whom there was no information on travel history, and 19 were
derived from patients with a history of travel in the Old World. In this study, a
sample was considered positive when the results of at least one of the assays
performed were positive. Assays were repeated independently to exclude con-
tamination.
Specimen processing and DNA preparation. Skin, duodenal, and gastric bi-
opsy specimens arrived in 0.9% NaCl or another physiological transport medium
and were first cut into smaller pieces with a sterile scalpel in a petri dish. They
were then transferred with the medium into a 2-ml tube, pelleted by centrifuga-
tion, and finally resuspended in 500 l of lysis buffer (10 mM Tris-HCl [pH 8.0],
5 mM EDTA, 0.5% sodium dodecyl sulfate).
Lesion aspirates were centrifuged at 8,000  g for 10 min and resuspended in
500 l of lysis buffer.
Anticoagulated bone marrow samples were centrifuged for 15 min at 800  g.
The buffy coat was transferred to a new tube, washed with phosphate-buffered
saline (PBS), pH 7.4, and resuspended in 500 l of lysis buffer. Coagulated clots
of bone marrow samples were treated like skin biopsy samples as described
above.
EDTA-anticoagulated blood was mixed with an equal volume of PBS, pH 7.4,
layered over Ficoll-Paque PLUS (density, 1.077 g/liter; Amersham Biosciences
Europe GmbH, Du¨bendorf, Switzerland), and spun for 30 min at 400  g The
interphase containing peripheral blood mononuclear cells was carefully trans-
ferred to a fresh tube, washed twice with PBS, pH 7.4, and resuspended in 500
l of lysis buffer.
Small sections (not more than 25 mg) of paraffin-embedded tissue samples
were scratched with a sterile scalpel into a 1.5-ml tube. Paraffin was removed by
being washed once with 1.2 ml of xylene and two times with 1.2 ml of ethanol.
Residual ethanol was evaporated by incubating the tube for 15 min in a heating
block at 37°C. The pellet was resuspended in 180 l of buffer ATL (QIAamp
DNA Mini Kit; Qiagen AG, Basel, Switzerland), and DNA was extracted and
purified by using the QIAamp DNA Mini Kit according to the QIAamp DNA
Mini Tissue protocol.
Generation of the positive control template. A 498-bp fragment of the cysteine
protease cpb2 gene from Leishmania mexicana (accession no. AJ319727; nucle-
otides 1302 to 1800), designated as the positive internal control in the miniexon
PCR assay (6) was amplified by PCR by using primers cpb2fw (5-TGA TCA
CCA CGA AGG AGT GC-3) and cpb2rev (5-ACG CGA GGG CAC GCG
AGG-3). Miniexon primer sites were introduced by subsequent nested PCR
with the composite primers cpb2Mifw (5-TAT TGG TAT GCG AAA CTT
CCG TGA TCA CCA CGA AGG AGT GC-3) and cpbMirev (5-ACA GAA
ACT GAT ACT TAT ATA GCG ACG CGA GGG CAC GCG AGG-3). PCR
mixtures (50 l) and cycling conditions for all the reactions were the same as
those for the miniexon PCR described below. PCR products were purified by
size-selective polyethylene glycol precipitation and cloned by using the pGEM-T
vector system (Promega, Madison, Wis.) according to the manufacturer’s instruc-
tions. Plasmid DNA containing the positive control template was purified by
using the CONCERT Rapid Plasmid Miniprep system (Invitrogen Life Tech-
nologies, Basel, Switzerland) according to the manufacturer’s manual. Purified
plasmid DNA was stored in Tris-EDTA, pH 8.0, containing 0.05% W-1 (Invitro-
gen Life Technologies).
PCR assays. For repetitive sequence PCR (Leishmania genotyping [LEG]
PCR) (28), primers T2 (5-CGG CTT CGC ACC ATG CGG TG-3) and B4
(5-ACA TCC CTG CCC ACA TAC GC-3) were used to amplify a repetitive
DNA sequence from Old World Leishmania. Two microliters of DNA solution
was amplified in a 100-l reaction mixture containing 50 mM PCR buffer, 0.2
mM deoxynucleoside triphosphates, 1.5 mM MgCl2, 0.5 M (each) primers, and
0.5 U of Taq DNA polymerase (Invitrogen Life Technologies). PCR amplifica-
tion was carried out in a DNA Thermal Cycler 480 (Perkin Elmer, Boston,
Mass.). After an initial denaturation step (5 min at 96°C), 40 cycles of 96°C for
30 s, 56°C for 45 s (annealing), and 72°C for 60 s (extension) were performed. For
miniexon PCR, primers Fme (5-TAT TGG TAT GCG AAA CTT CCG-3) and
Rme (5-ACA GAA ACT GAT ACT TAT ATA GCG-3) were used to amplify
the nontranscribed spacer region of the miniexon sequence of Leishmania (24).
Two microliters of DNA solution was amplified in a 50-l reaction mixture
containing 50 mM PCR buffer, 0.2 mM deoxynucleoside triphosphates, 1.5 mM
MgCl2, 40 mM tetramethylammonium chloride, 12% dimethyl sulfoxide, 0.5 M
(each) primers, and 0.5 U of Taq DNA polymerase. The positive control tem-
plate was added to a final concentration of 250 fg (corresponding to approxi-
mately 70,000 plasmid copies) per reaction mix. The PCR amplification was
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carried out in a Mastercycler gradient 5331 (Eppendorf, Hamburg, Federal
Republic of Germany). After an initial denaturation (5 min at 94°C), 35 cycles of
94°C for 30 s, 54°C for 30 s, and 72°C for 45 s were performed.
Genotyping. Typing of the Leishmania species was achieved by RFLP analysis
of the amplified miniexon gene. Ten microliters of the miniexon PCR products
was digested with the restriction enzymes according to the genotyping scheme
described elsewhere (24).
In order to confirm our genotyping results, DNA aliquots from all the samples
found to be positive by PCR were analyzed by two other PCR-RFLP genotyping
schemes based on the sequence differences in the genomic repeat of Old World
Leishmania (30) and the ITS region of the SSU rRNA gene (37a).
Cultivation of parasites. The culture medium, a 1:1 mixture of SDM-79 (7)
and SM (8) complemented with 15% heat-inactivated fetal bovine serum, was
supplemented with an anticontamination cocktail consisting of penicillin G
(60 g/ml), kanamycin (100 g/ml), chloramphenicol (10 g/ml), and flucytosine
(50 g/ml). The medium was directly inoculated with the patient specimens and
incubated at 27°C without gas phase in T-25 tissue culture flasks (Falcon, BD
Biosciences, Allschwil, Switzerland). Cultures were checked for the presence of
promastigote forms of Leishmania by examination with an inverted microscope.
Microscopic examination was done every 2 days for up to 15 days.
Serology. Serum samples were tested for anti-Leishmania antigen antibodies
by using an IFAT. Twelve-well slides were coated with imprint preparations of an
L. donovani-infected hamster spleen and stored at 80°C. Slides were defrosted,
fixed with acetone for 10 min at room temperature, and dried under ventilation.
The wells on the slides were covered with 25 l of serial twofold dilutions (1:40
to 1:1,280 in PBS, pH 7.2) of the sera and incubated in a humid chamber for 30
min at 37°C. After three washes with PBS, pH 7.2, 25 l of fluorescein isothio-
cyanate-labeled goat anti-human immunoglobulin G (Biome´rieux, Marcy
l’Etoile, France) diluted 1:80 in Evansblue (0.1 mg/ml of PBS, pH 7.2) was
applied to each well. After incubation in a humid chamber for 30 min at 37°C and
three washes with PBS, pH 7.2, the slides were dried under ventilation, mounted
with 50% (vol/vol) glycerol-PBS, and covered with a coverslip. Staining of the
samples was assessed by examination with a fluorescence microscope and com-
pared with that of positive and negative controls. Samples showing fluorescence
with serum dilutions higher than 1:80 were regarded as positive.
RESULTS
Application of the miniexon PCR assay to clinical samples.
In order to identify inhibitory effects in the PCR due to impu-
rities in the sample and to assess tube-to-tube variations in
PCR efficiencies, the test was set up with an internal positive
control. The sensitivity of the assay was not compromised by
the coamplification of the positive control template (data not
shown), and a concentration of 250 fg of plasmid DNA (cor-
responding to about 70,000 plasmid copies) per reaction mix
produced a clear band in the PCR assay. From a total number
of 50 clinical samples, DNA was purified and tested with the
miniexon PCR assay. DNA from each sample was coamplified
along with the positive control template. Of the 26 DNA sam-
ples which gave a positive result, the majority outcompeted the
positive control template (Fig. 1, lanes 3 and 4), whereas in the
remaining samples the signals of both the Leishmania and the
positive control were visible on the agarose gel (Fig. 1, lanes 1
and 2). The other 24 samples were negative in the assay (Fig.
1, lane 8). PCR inhibition was observed in 6 of the 50 samples
(Fig. 1, lane 5). Inhibition was resolved in two samples after a
10-fold dilution, after which one sample became positive (Fig.
1, lane 6) and one was determined to be negative. The remain-
ing four samples had to be purified again by using the QIAamp
DNA Mini Kit, after which two became positive (Fig. 1, lane 7)
and two were determined to be negative.
Comparison of the diagnostic assays. The miniexon PCR
assay was compared to the methods currently applied at the
STI for the diagnosis of leishmaniasis (i.e., in vitro cultivation
and serology) and a PCR assay which is based on the amplifi-
cation of a repetitive genomic sequence of Old World Leish-
mania (LEG PCR assay) (28). All tissue samples, which were
obtained from patients with a tentative diagnosis of leishman-
iasis on clinical grounds, were tested with the LEG and the
miniexon PCR assays, and 38 of them were inoculated into
culture. Corresponding serum samples, available from 16 pa-
tients, were analyzed for anti-Leishmania antigen antibodies by
IFAT. Results are summarized in Table 1. For a limited com-
parison, only positive samples were tested by the PCR assay
using the ITS region of the SSU rRNA gene (37a).
No single test could serve as a “gold standard” against which
the different assays could be evaluated. Therefore, assessment
of test performance (Table 2) was based on the assumptions
that (i) a patient was positive for leishmaniasis when the in-
fection was detected by at least one of the diagnostic assays and
(ii) a patient was negative for leishmaniasis when results of all
four assays (including serology) were negative. A Leishmania
infection was diagnosed in 29 patients. Two infections were
detected by all four methods, 12 infections were detected by
FIG. 1. Coamplification of Leishmania DNA from clinical samples
and a positive control template. Black triangles denote the 540-bp
band of the positive control template, and grey triangles correspond to
the Leishmania-specific PCR signal. Lanes 1 and 2, positive samples.
The PCR products of the target DNA and the positive control tem-
plate are visible on the agarose gel. Lanes 3 and 4, positive samples.
Target DNA outcompeted the positive control template. Lane 5, PCR
inhibition is indicated because the positive control template is not
visible. Lane 6, previously inhibited sample after DNA dilution. Lane
7, previously inhibited sample after subsequent purification. Lane 8,
negative sample with only control template visible.
TABLE 1. Diagnostic results for clinical samples
Specimen
type
Total no.
of positive
samplesa
No. of samples positive by:
Culture LEGPCR
Miniexon
PCR
Serol-
ogyb
SSU-ITS
PCR
Skin biopsy 12 6 8 12 4 6
Bone marrow 7 2 7 4 3 3
Lesion aspirate 1 0 1 1 0 1
Bloodc 2 2 2 2 0 1
Duodenal biopsyd 2 1 2 2 0 1
Gastric biopsyd 1 1 1 1 0 1
Paraffin-embedded
skin biopsy
4 0 2 4 1 1
Total 29 12 23 26 8 15
a Leishmaniasis confirmed by at least one of the diagnostic tests.
b For patients from whom a corresponding serum sample was available.
c Supplemented with EDTA.
d From patients positive for HIV.
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three methods, and 10 infections were detected by two meth-
ods. In five patients, the presence of a Leishmania infection
was confirmed by one method only (four cases were confirmed
by the miniexon PCR assay, and one was confirmed by the
LEG PCR assay).
In vitro cultivation was performed for a total of 38 samples.
No cultures were set up from the four paraffin-embedded spec-
imens, and results for eight specimens are missing because
either they were lost due to contamination or there was no
request for this test. Twelve of 17 Leishmania-positive samples
were detected by cultivation, of which one infection was con-
firmed by one other test, 13 were confirmed by two other tests,
and three were confirmed by three other tests, resulting in a
sensitivity of 70.6%. The remaining 21 samples with a negative
culture result were also negative by both PCR assays, giving a
specificity of 100%.
Sixteen serum samples were available to test by IFAT for
anti-Leishmania antigen antibodies. This test identified eight
positive samples from 14 patients whose infections were con-
firmed by other assays (two were confirmed by three other
tests, three were confirmed by two other tests, and three were
confirmed by one other test) but failed to diagnose the infec-
tion in six samples determined to be positive by other assays,
giving a sensitivity of 57.1%. Two serum samples available
from patients without an infection, as confirmed by all other
tests, were also negative (specificity, 100%).
The LEG PCR detected Leishmania in 23 of the 29 positive
samples, giving a sensitivity of 79.1%, but failed to diagnose the
infection in six specimens that were confirmed to be positive by
other tests. Parasites in all six samples for which no PCR
product was obtained were subsequently identified by mini-
exon RFLP analysis as Leishmania species from the New
World, resulting in a sensitivity of 100% for Old World species
only. Specificity of the LEG PCR assay was 100% with all
samples which were also negative by all other tests, but one
sample was positive only with this test and was not confirmed
to be positive by any of the other tests.
The PCR-RFLP genotyping assay based on the ITS region
of the SSU rRNA gene detected a Leishmania infection in 15
of the 29 samples and gave a sensitivity of 51.7%. Because we
tested only samples previously identified as positive, we were
not able to determine the specificity of the assay.
The miniexon PCR detected Leishmania in 26 of the 29
positive samples and gave a sensitivity of 89.7% but failed to
diagnose the infection in three specimens, of which two infec-
tions were confirmed by the LEG PCR assay and positive
serology and one was confirmed by the LEG PCR assay only.
It is worth mentioning that these three DNA samples were all
derived from bone marrow specimens and were freeze-thawed
several times. All the 21 Leishmania-negative patients were
negative by the miniexon PCR assay (specificity, 100%), but it
should be noted that four of the 29 positive results were not
confirmed by any other test.
Genotyping of Leishmania spp. by RFLP analysis. All sam-
ples positive by the miniexon PCR assay were subjected to
RFLP analysis of the amplification product (24). No unusual or
ambiguous RFLP patterns occurred, and Leishmania from all
positive samples could be assigned to a given species according
to the typing scheme. The species in 15 of the 26 positive
samples was identified as L. infantum, that in four samples was
identified as L. major, those in one sample each were identified
as L. tropica and L. mexicana, that in three samples was iden-
tified as L. braziliensis, and that in two samples was identified
as L. guyanensis.
Species in the 23 samples positive by the LEG PCR assay
were typed by RFLP analysis as belonging to the Old World
species L. infantum (n  14), L. donovani (n  4), L. major
(n  4), and L. tropica (n  1).
DNA aliquots of the samples from the 29 Leishmania-posi-
tive patients were also analyzed by the PCR-RFLP genotyping
assay, which is based on sequence variations in the ITS region
of the SSU rRNA gene (37a). With this assay, species from
positive samples were typed at the complex level. They were
assigned to the L. donovani (n 7), L. major (n 6), L. tropica
(n  1), and L. braziliensis (n  1) complexes.
A summary of the genotyping results is given in Table 3.
There was a good correlation between the results obtained
with the LEG and miniexon genotyping schemes. However, the
LEG PCR system cannot detect any of the New World species,
and a species from four samples typed as L. donovani with the
LEG PCR system was typed as L. infantum with the miniexon
system. There was also a good correlation between the results
of the miniexon and ITS genotyping schemes, except that a
species from two samples typed as L. infantum by the miniexon
system was assigned to the L. major complex by the ITS system.
These two samples were two of the four samples with a species
typed as L. donovani by the LEG PCR system.
TABLE 2. Comparison of the diagnostic assays
Assay (total)a
No. of positiveb samples/no. of tested samples
Sensitivity
(%)Skin biopsy
specimens
Bone marrow
samples
Blood
samples
Duodenal biopsy
specimensc
Gastric biopsy
specimens
Lesion
aspirates Total
In vitro cultivation (38) 6/9 3/5 1/1 1/1 1/1 NA 12/17 70.59
Serology (16) 5/9 3/4 0/1 NA NA NA 8/14 57.14
LEG PCR (50) 10/16d 7/7 2/2 2/2 1/1 1/1 23/29 79.31 (100)d
SSU-ITS PCR (29)e 7/16 3/7 1/2 2/2 1/1 1/1 15/29 51.71
Miniexon PCR (50) 16/16 4/7 2/2 2/2 1/1 1/1 26/29 89.66
a Total number of samples subjected to each assay.
b Leishmaniasis confirmed by at least one of the diagnostic tests.
c NA, not applicable.
d All negative samples were subsequently shown to be infected with New World species; therefore, sensitivity for Old World species was adjusted to 100%.
e Only samples that were previously identified as positive by other assays were tested.
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DISCUSSION
Detection of Leishmania parasites in a clinical sample is
necessary to confirm a suspected case of leishmaniasis. Most
commonly used methods for the direct detection of the para-
site (e.g., microscopic examination of Giemsa-stained smears
and in vitro cultivation) lack sensitivity because of the paucity
of Leishmania parasites in some specimens (42) or are ham-
pered by the problem of contamination (3). Indirect methods
(e.g., detection of anti-Leishmania antigen antibodies by sero-
logical methods) are also limited in sensitivity and are not able
to discriminate between past and current infections. The ad-
vent of the PCR technology has opened new avenues in the
diagnosis of leishmaniasis, and several approaches have been
developed during the last two decades (11, 43). Most of these
assays are based on highly repetitive genomic gene loci or
extrachromosomal kinetoplast DNA sequences, but their use is
confined to the detection of the parasite at genus (5, 25) or
complex (10, 13) level, and therefore, their application is lim-
ited to restricted geographical areas and diagnostic settings.
Our assay was developed for use in a diagnostic setting
where patients with a history of global travel are seen. It was
the aim of this study to optimize and evaluate a recently de-
veloped PCR-RFLP-based genotyping assay for Leishmania
species. The assay targets the miniexon gene of the parasite
and has proven to be simple and cheap; i.e., the detection of all
Leishmania spp. is accomplished by one PCR with all-encom-
passing primers. It has a sufficient sensitivity, high specificity,
and the ability to differentiate between all clinically relevant
Leishmania species by RFLP analysis of the PCR product (24).
The inclusion of a positive control template makes it possi-
ble to detect inhibitory effects in the PCR mix and also controls
for tube-to-tube variation both within and between different
PCR experiments. Several methods are available for the design
and construction of an internal positive control, some of which
were successfully used in PCR assays for Leishmania. These
include the coamplification of the human -globin gene in a
multiplex PCR approach (27), the use of a competitive PCR
assay with heterologous plasmid sequences (25), and the use of
synthetic probes in the reaction (4). We used a competitive
PCR assay targeting a 498-bp fragment of the cpb2 gene of L.
mexicana. This fragment is slightly larger than our target se-
quence, has a GC content similar to that of the miniexon
sequence, and is free of any restriction sites required for sub-
sequent RFLP analysis of the miniexon sequence. In all assays,
this positive control template yielded a clearly distinguishable
PCR product, and coamplification did not affect assay sensi-
tivity or compromise amplification of the miniexon sequence
and never interfered with subsequent RFLP analysis (data not
shown).
Fifty patient samples were available for the validation of the
assay, and samples were subjected in parallel to a second PCR
assay (LEG PCR) (28). When possible, samples were cultured,
and serum samples were tested for Leishmania-specific anti-
bodies. As expected, PCR assays were by far more sensitive
than the currently applied diagnostic methods. Successful cul-
ture is dependent on the presence of viable organisms, and
growth requirements are known to differ between species (3).
IFAT failed to detect six infections (those of four patients with
cutaneous manifestations and those of two patients suspected
to have visceral leishmaniasis) which were all confirmed by at
least two other tests. This failure might reflect the generally
lower sensitivity of serological assays for detection of cutane-
ous forms of the disease (21) or might be due to a lack of
cross-reactivity with the antigens on which the assay is based
(26). Furthermore, humoral responses in patients with a con-
current HIV infection or other causes of immunosuppression
may be moderate or even absent (1). Indeed, all three samples
obtained from HIV-positive patients were negative by the se-
rological assay.
The LEG PCR assay was tailored for the characterization of
Old World Leishmania and consequently failed to detect six
infections by parasites subsequently typed as New World spe-
cies by the miniexon assay. On the other hand, the miniexon
assay failed to detect three infections by parasites typed as Old
World species by the LEG assay, which might be due to lower
sensitivity of the miniexon PCR. However, storage of DNA
from these three patients might also have compromised the
results of the miniexon PCR.
Proper sampling is crucial for the establishment of a reliable
diagnostic assay for leishmaniasis, and basic questions, such as
what the optimal site of sample collection is (32) and whether
blood samples are sufficient for a reliable diagnosis, remain
open. Hematogenous dissemination has been described for L.
donovani, L. infantum, L. tropica, and L. braziliensis (J. Kubar,
J. F. Quaranta, P. Marty, A. Lelievre, Y. Le Fichoux, and J. P.
Aufeuvre, Letter, Nat. Med. 3:368, 1997), and PCR-based as-
says on blood samples have proven useful for the diagnosis and
monitoring of visceral leishmaniasis in adults and children in
the Mediterranean region, as well as in HIV-coinfected pa-
tients (15, 19). The four blood samples in our study were
processed only after the request for an additional tissue sam-
ple, and their analysis confirmed the results obtained with the
other analyzed specimens.
The miniexon PCR assay was more sensitive than the con-
ventional diagnostic methods and capable of detecting infec-
tion in a wide range of clinical samples, including paraffin-
embedded tissue samples. This is of advantage since tissue
biopsy specimens are often fixed and embedded in paraffin for
histological examinations. Application of the PCR assay to
paraffin-embedded specimens prevents repeated invasive sam-
TABLE 3. Results from three PCR-RFLP genotyping
schemes for Leishmania spp.
No. of
patients
Species or complex identified bya:
LEG-RFLP
typing
Miniexon
RFLP typing
ITS-RFLP
typing
1 ND L. braziliensis L. braziliensis complex
2 ND L. braziliensis ND
2 ND L. guyanensis ND
1 ND L. mexicana ND
1 L. tropica L. tropica L. tropica complex
4 L. major L. major L. major complex
7 L. infantum L. infantum L. donovani complex
4 L. infantum L. infantum ND
3 L. infantum ND ND
2b L. donovani L. infantum ND
2b L. donovani L. infantum L. major complex
a ND, not determined (PCR test failed to detect the infection).
b Discordant results.
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pling if a differential diagnosis of leishmaniasis is required and
might be useful for the investigation of archived samples. It is
noteworthy that other PCR-based assays have reported a high-
er sensitivity. Yet, these assays detect the presence of Leish-
mania parasites rather than individual Leishmania species. Al-
though we found the miniexon assay to show a high sensitivity,
other assays might be preferable for samples in which very low
densities might be expected.
Prior to the development of biochemical or molecular tools
for the characterization of Leishmania, diagnosis of leishman-
iasis relied on clinical and epidemiological criteria. Over the
past few years, the reports of atypical clinical manifestations
have accumulated, challenging this traditional classification.
This includes reports of visceral leishmaniasis caused by the
dermotropic species L. tropica and L. mexicana (23) and the
occurrence of cutaneous manifestations caused by L. chagasi
and L. infantum, which usually cause visceral leishmaniasis (31;
J. A. Rioux and G. Lanotte, Letter, Trans. R. Soc. Trop. Med.
Hyg. 84:898, 1990).
Therefore, correct classification of infecting Leishmania spe-
cies can provide important complementary information for the
clinician that may result in modified clinical prognosis, as well
as initiation of species-specific therapeutic approaches (3).
Furthermore, identification of the infecting species is impor-
tant in monitoring therapy. In areas where different species are
sympatrically transmitted, discrimination between relapse of a
latent infection and reinfection by another species is important
in cases of reemerging leishmaniasis.
In order to appraise the validity of the miniexon genotyping
scheme, we typed the samples with two other PCR-RFLP-
based methods, the LEG and the ITS system. Although no
unusual patterns were encountered with any of the genotyping
schemes and the correlation between the results of all the
systems was satisfying (Table 3), some discrepancies were ob-
served. Because the biological species concept is difficult to
apply to Leishmania and there is as yet no agreement on the
definition of the species boundaries within the genus (2), none
of the genotyping systems could actually serve as a gold stan-
dard for the evaluation of the others. We observed four dis-
crepancies, two in which data obtained with the miniexon PCR
suggested the presence of L. infantum but LEG PCR identified
L. donovani. Although Leishmania has been thought to be
clonal (2), hybrid forms within the L. donovani complex might
occur. Using independent single marker genes cannot exclude
this possibility. Discrepant identification of L. infantum and
L. major in two cases cannot be explained but might reflect a
laboratory artifact. Previously, the miniexon genotyping system
has been tested with both World Health Organization refer-
ence strains and culture isolates from the STI, all indepen-
dently characterized by isoenzyme analysis, and the results
were in good yet not perfect concordance with the species
definitions (24).
In conclusion, the miniexon PCR-RFLP-based genotyping
assay has proven to be a reliable test for the detection of
Leishmania in a wide range of clinical samples obtained from
a travel clinic. The standardization of the test as a competitive
assay including the coamplification of an internal positive con-
trol template has turned out to be a valuable tool for the
assessment of PCR performance. We have demonstrated that
the assay is quick and easy to perform and shows in this study
a higher sensitivity than conventional diagnostic methods.
Moreover, it enables the characterization of the parasite at
species level by a simple method within a reasonable time
frame and provides a useful tool for the characterization of
clinically relevant Leishmania species, which can help the cli-
nician choose an adequate therapeutic approach.
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3.4. Discussion 
 
Sexual reproduction has not yet been shown in Leishmania, so the term ‘species’ 
might not be correctly used for all known strains. As example, L. infantum and L. 
chagasi, as well as L. major and L. venezuelensis are believed to be genetically 
identical, only the geographic distribution differs. Therefore, L. chagasi and L. 
venezuelensis most probably derived from dogs infected by L. infantum and L. major 
respectively, which had been imported during settlement of the Americas by 
Europeans. Sequencing of the mini-exon genes supports this hypothesis. 
Furthermore, the mini-exon genes of L. colombiensis and L. naiffi showed high 
homology. 
Although the mini-exon gene is present in kinetoplatids, nematodes and even 
chordates, the specifity of the PCR for Leishmania is given, since DNA of 
Trypanosoma and nematodes lacks proper binding sites of our primers. However, 
PCR using DNA of Chritidia (parasitic kinetoplastids, living in insects) as template 
yielded an amplification of the mini-exon gene but the resulting restriction patterns of 
the PCR products were completely different from Leishmania patterns. 
The mini-exon PCR proved to be a great tool for confirming an suspected Leishmania 
infection and distinguishing the infecting species at the same time. However, it is 
important to note that when diagnosing Viannia species a single point mutation within 
the restriction site can change the interpretation of the results. As L. brasiliensis and 
L. guyanensis differ in the required treatment, but their mini-exon genes differ solely 
by a few point mutations, another genetic marker should be used for these species. 
However, the mini-exon PCR was not designed as solely tool used for diagnosis, but 
as an additional method to confirm interpreting of the symptoms and classical 
diagnostic tools, such as cultivation of the parasites. 
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4. Identification of genes encoding potential 
virulence factors, drug targets and vaccine 
candidates of L. infantum. 
 
 
4.1. Background 
 
For establishment of a successful infection in the vertebrate host, Leishmania 
parasites are involved in the following events: 
1. Evasion of the humoral lytic factors. 
2. Attachment to macrophages following endocytosis of the parasites. 
3. Survival within the harsh conditions of phagolysosomes. 
4. Differentiation from pro- to amastigotes. 
5. Replication of the amastigotes. 
6. Infection of ‘empty’ macrophages by amastigotes. 
These events yield in escape from the host’s innate immune system by intracellular 
parasitism. Furthermore, the parasite enhances its pathogenity by triggering the 
immune answer towards a non-protective TH2 type answer, resulting in establishment 
of a long lasting infection. All parasite factors involved in these processes can be 
defined as virulence factors. However, in a broader range, virulence can not solely be 
enhanced by factors involved in host-parasite interactions but also by unspecific 
processes as high replication rate. The whole complexity of this area is shown in 
figure 4. 
While some Leishmania virulence factors are known - as GP63 (inhibition of 
complement mediated lysis, reviewed by Yao et al. (2003) or LPG (survival within 
phagolysosomes, Spath et al., 2003) -, many others may have not yet been 
discovered. 
In order to identify potential virulence factors, a cDNA subtraction was performed 
using metacyclic (transmission) stage cDNA from a strain of low infectivity and a 
strain of high infectivity: 
 highly infective strain 
- low infective strain______
 potential virulence factors 
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Figure 4 (from (Rivas et al., 2004). A global view of virulence. Clinical outcome is a direct 
consequence of virulence, when considered in a broad sense. There are three main virulence factors 
(indicated in red): intrinsic virulence; parasite burden; and host factors. Intrinsic virulence is the 
addition of single actuations of the different groups of virulence factors, together with intertwined 
actions among them, grouped under the term virulence networks. Some of the representative 
examples of the corresponding groups are indicated in blue. At the same time, the host plays a major 
role in clearing parasite burden either through the immune response or chemotherapy (indicated in 
orange).This figure is partially based on the concepts developed by Chang et al. (2003). In the case of 
natural infections, chemotherapy will be deleted and, from an epidemiological background, other 
factors, such as virulence inside the vector or the vector–mammal relationship, must be incorporated. 
Abbreviations: GIPL, glycoinositolphospholipid; Gp63, glycoprotein 63 KDa (leishmaniolysin); HSP, 
heat-shock protein; LACK, Leishmania homologue of receptors for activated C-kinase; LeiF 
Leishmania elongation initiation factor; LPG, lipophosphoglycan; RACKs, receptors for activated C 
kinase; SOD,.superoxide dismutase. 
 
 
However, the two strains differed not solely in infectivity, but also in growth rate 
(which of course has a great impact on virulence). Nevertheless, higher growth rate is 
achieved by up regulation of many genes, for which association with virulence can 
hardly be determined. Although late stationary phase cultures (consisting mostly of 
non-dividing metacyclics) were used for the subtraction, many of the genes we 
selected were indeed up regulated in the highly infective strain, but could not be put 
into relation with virulence - as translation elongation factors and histone H1.  
Therefore, the experiment was redesigned. cDNA of non-infective vector stages was 
subtracted from the infective vector stage of the same strain: 
 infective stage 
- non-infective stages_____
 potential virulence factors 
Since the latest vector stage, the metacyclic stage is the only vector stage capable of 
infecting macrophages, early vector stages were subtracted from late stages. For 
successful transmission, metacyclis escape from the complement, and have to be 
phagocytized by macrophages, where they must survive within phagolysosomes and 
differentiate into amastigotes. Furthermore, one could speculate that metacyclic 
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parasites are also involved in triggering the host’s immune answer towards a non-
protective direction, since metacyclics are the first parasites seen by the immune 
system. Consequently, many virulence factors can be assumed to be expressed 
within this parasite stage. 
For the same reason, transmission blocking vaccine candidates might be identified, if 
putative membrane proteins expressed at metacyclic’s surface would be discovered 
(anti-bodies against a flagellum specific epitope were already shown to inhibit 
adherence of promastigotes to phagocytes, Singla and Vinayak, 1994). 
Furthermore, identification of proteins of metacyclic parasites which show no 
homologies to mammal proteins might be regarded as potential drug targets for both, 
prophylaxis and treatment (for the latter purpose only when these proteins are also 
expressed in amastigotes). 
 
 
4.2. Methods 
 
We used suppression subtractive hybridization (SSH, Diatchenko et al., 1996) as 
described below. Since most of the mRNAs in Leishmania contain a 5’ conserved 
sequence, two simplifications of the SSH method were tested. 
 
SSH  
Using this method (figures 5 and 6A), ds cDNA was the starting material for both, 
tester and driver (the driver is subtracted from the tester). The ds cDNA was cut with 
a suitable restriction enzyme leading to fragment sizes of 100 to 500 bases. In 
contrast to the driver, half of the tester was ligated to adaptor1, the remaining tester 
to adaptor2. In two hybridization steps, pre-subtracted tester1 and 2 were finally 
combined. This led to formation of a hybrid of tester 1 and 2. Prior to PCR, the ends 
were filled in. For selection of the tester hybrid, a suppression PCR was performed 
using adaptor primers. Since the 5’ ends of both adaptors consisted of a palindromic 
sequence, DNA strands containing the same adaptors at both ends could form a loop 
and thus were not efficiently amplified (suppression PCR). In contrast, the tester 
hybrid containing 2 different adaptors at both ends was amplified exponentially and 
could be subsequently ligated into a cloning vector.  
 
Modification1  
In this method (figures 5 and 6B), tester and driver were obtained by generating 
cDNA using the spliced leader sequence. Tester 1 was amplified using a short 
spliced leader primer and RT-primer1. For Tester 2, a long spliced leader primer and 
RT-primer2 was used, and amplification of the driver was done using the short 
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spliced leader primer and RT-primer1. The hybridization scheme was the same as for 
SSH above. The hybrid of tester 1 and 2 could be selected by PCR (using the very 
5’end of the mini-exon as forward and RT-primer1 as reverse primer). 
 
 
 
 SSH    modification1  modification2  
 
   
total RNA   total RNA   total RNA 
     ↓     
mRNA enrichment 
     ↓         ↓         ↓  
mRNA  
     ↓ 
reverse transcription  reverse transcription  reverse transcription 
     ↓         ↓         ↓ 
ss cDNA   ss cDNA   ss cDNA 
     ↓         ↓         ↓ 
2nd strand synthesis   PCR    PCR 
     ↓         ↓         ↓ 
ds cDNA   tester and driver  tester and driver 
     ↓ 
restriction digest 
     ↓ 
driver 
     ↓         ↓         ↓ 
adaptor ligation 
     ↓ 
tester     
     ↓ 
subtractive hybridizations  subtractive hybridizations  subtractive hybridizations 
     ↓         ↓      
suppression PCR  PCR         ↓ 
     ↓         ↓ 
ligation    ligation    ligation 
     ↓         ↓         ↓ 
transformation   transformation   transformation 
     ↓         ↓         ↓ 
subtraction library  subtraction library  subtraction library 
 
 
Figure  5: production steps required for SSH and its modifications. 
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A Driver
(in excess)
Tester 1 Tester 2
 
 
Figure 6: details of SSH (A) and modifications (B and C, next page) 
 hybrid of tester 1 and 2 
(the tester ‚survived‘ 2 rounds of subtraction) 
fill in the ends
PCR with adaptor 
primers 
suppression
linear  
amplification
 
      mix, 
   denature 
and hybridize
ds tester
tester-driver hybrid
ds driver
ss driver
ss tester
no adaptor
with adaptor 2with adaptor 1 
Driver
(in excess)
add denatured driver 
 and combine the two samples
tester 
hybrid 
no amplification 
exponential 
amplification
unsubtrcted 
tester 
ss tester 
tester-driver 
hybrid 
driver 
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DriverTester 1 Tester 2 
 
same hybridization    scheme as SSH 
fill in end
tester hybrid 
PCR
 linear amplification of unsubtracted tester and driver. 
Tester 1 Driver Tester 2 
Exponential amplification of subtracted tester,B 
5‘ SL primer
RT primer1 
3‘ SL primer 
RT primer1 
3‘ SL primer 5‘ SL primer 
RT primer2 RT primer2
phosphorylated unphosphorylated primers
-P      SL primer 
phosphory-  
 P- 
P- 
P- 
-P 
-P 
no more than 
one end  
phosphorylated 
ligation
tester 
hybrid 
both ends phsphorylated
clones 
ligation
no 
clones
P- 
-P
C
lated RT-primer
 
same hybridization scheme as SSH 
Figure 6: details of SSH (A, previous page), modification1 (B) and modification2 (C) 
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Again, tester and driver were obtained using spliced leader RT-PCR (figures 5 and 
6C). For tester1, the spliced leader primer but not the RT-primer was phophorylated, 
in contrast to tester2, where the RT-primer but not the spliced leader primer was 
phosphorylated. The driver was amplified using non-phosphorylated primers.  
Because the hybrid of tester1 and 2 was the only ds DNA in the hybridizytion mix 
which was phosphorylated at both ends, it could be selected by ligation. It could 
either be directly ligated into a blunt end cut and dephosphorylated vector, or ligated 
to non-phosphorylated adaptors (using subsequently PCR with adaptor primers as 
method for selection of the subtracted tester).  
 
The advantages of both modifications would be: 
• total RNA (not only mRNA) could be used as starting material 
• PCR instead of second strand synthesis 
? subtraction using limited amounts of RNA possible 
• no restriction digest of tester and driver 
? subtraction library would contain full length cDNA resulting in 
simplification of gene identification. 
  Furthermore, selecting of different fragments belonging to the  
 same gene would be avoided. 
• no adaptor ligation prior to subtraction. 
? Blunt end ligation, as used in SSH, usually lacks high efficiency. 
 
However, changes in hybridization conditions (DNA concentration, buffer, 
temperature) yielded in completely different band patterns after the final PCR using 
the modified subtraction methods. Since too many optimization steps would have 
been necessary to get to work both modifications in a reliable manner, both methods 
were not developed beyond the state of testing. Nevertheless, the potential of the 
second modification was promising, due to its simplicity. 
 
SSH was used for both strain and stage subtractions. For the strain subtraction, 
amplified spliced leader cDNA was the starting material, whereas the protocol of 
Clontech’s PCR select subtraction kit was followed for the stage subtraction. 
The differentially expression patterns of the clones were performed by Northern blot 
analysis and their sequence was analyzed using motif scans and basic local 
alignment search tools (BLAST). In order to perform localization studies, three clones 
of the stage subtraction library were recombinantly expressed in E. coli, and the 
purified proteins were used to immunize mice. 
 
 
 35
4.3. Differentially expressed genes in Leishmania infantum 
promastigotes 
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  36.1 
 Abstract 
 
Suppression subtractive hybridization technology was used to select Leishmania 
infantum promastigote genes that show differential expression in early logarithmic 
phase and stationary phase parasites. Several genes showing differential 
expression were identified and eight were selected for further analysis. Increased 
expression in stationary phase parasites was observed for 7 genes, while one 
selected gene was strongly down regulated in this phase. The selected genes 
encoded putatively for a glucose transporter, an amino acid transporter, a short 
chain dehydrogenase, a cytochrome b5 like protein, a protein probably involved in 
protein-protein interactions, proteins with unknown functions and the previously 
identified metacylogenesis associated transcript 1 (MAT-1). Larger sequences of 
the selected genes were generated using primer walking, and the cellular 
localization of the glucose transporter was determined by immunofluorescence. In 
this report we show that suppression subtractive hybridization can be used to 
identify growth stage specific genes of Leishmania, and that this approach can 
potentially identify drug or vaccine targets. 
  36.2 
 Introduction 
 
Visceral leishmaniasis (VL) caused by the protozoan parasite Leishmania infantum 
is usually fatal if not rapidly diagnosed and treated. Existing first line drugs for the 
treatment of VL, such as Pentostam and Glucamtin, are highly toxic and may 
cause severe side effects. Over the last ten years, there has been a sharp increase 
in the number of recorded cases and distribution of this disease (WHO, 
http://www.who.int/emc/diseases/leish/leishmaniasis.pdf), highlighting the need for 
better intervention strategies. Leishmania are transmitted as promastigotes by 
sandflies (Phlebotomus sp. and Lutzomyia sp.) to vertebrate hosts where they are 
endocytosed by polymorphonuclear phagocytes and dendritic cells. Following 
phagocytosis they differentiate inside phagolysosomes into amastigotes where 
they multiply and are responsible for disease. Several types of promastigote forms 
have been described in sandflies and culture, including dividing parasites (procyclic 
and nectomonad forms) and non-dividing parasites (metacyclic forms). Metacyclic 
parasites are of special interest since they are the infectious promastigote form 
transmitted by insect vectors to the mammalian host (reviewed by Killick-Kendrick, 
1990). 
Because metacyclic parasites are responsible for the establishment of a new 
infection, it is likely that genes responsible for virulence may be up regulated during 
this phase of promastigote growth. Three prominent parasite virulence factors, 
lipophosphoglycan (LPG), the major surface protease (MSP or gp63) and the 
amastigotes specific gene family A2, have been identified (Descoteaux and Turco, 
2002). LPG covers most of the metacylic form’s surface and has been shown to be 
structural different from LPG expressed on the parasite during other stages of 
growth (McConville et al., 1992). lpg1- mutants are highly susceptible to human 
complement, have lost the ability to inhibit phagolysosomal fusion transiently, and 
are oxidant sensitive (Spath et al., 2003). MSP is also considered a virulence factor 
(reviewed by Yao et al., 2003). This protein is encoded for by a gene family of 
which several show stage specific expression. MSP plays an important role in 
resistance to complement mediated lysis by converting the complement factor C3b 
to the inactive form C3bi (Brittingham et al., 1995) and may show additional 
functions as discussed by Yao et al. (2003). Finally Zhang and Matlashewski 
(1997) showed that products of the amastigote specific gene family A2 are required 
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 for virulence of L. donovani in mice.  
Since metacyclic promastigotes are exposed to environments seen by both stages 
of the parasite such as the sandfly vector, the vertebrate host’s blood, and 
macrophage phagolysosome, one might expect that they share potential drug 
targets with intracellular amastigotes. Therefore, identification metacyclic specific 
genes could reveal proteins that are essential for the infection of and survival in the 
macrophages. These proteins might represent interesting new targets for the 
development of new drugs or vaccines. As yet, no vaccine against any Leishmania 
species is in routine use, though several experimental vaccines are currently being 
tested (Ghosh and Bandyopadhyay, 2003). Because metacyclic parasites are 
exposed to the complement system and important in inducing initial B- and T-cell 
responses, surface molecules expressed at this stage might be exploited as 
potential vaccine candidates. Futhermore, resistance appears to be increasing 
against most drugs used to treat VL today and new drugs are urgently needed. 
Several techniques have been used successfully to identify metacyclic specific 
genes including differential screening of poly(A)+ RNA (Coulson and Smith, 1990), 
vectorette PCR amplified 3’ untranslated sequences (Coulson et al., 1997) and 
microarray analysis (Saxena et al., 2003). Within in vitro cultures, metacyclic forms 
are primarily found in stationary phase cultures. Since metacyclics appear to 
represent the most virulent promastigotes, we enriched for genes differentially 
expressed in this stage by suppression subtraction cDNA hybridization (SSH) 
technique (Diatchenko et al., 1996) of cDNA synthesized in late logarithmic and 
stationary phase cultures. Using SSH we were able to identify several differentially 
expressed genes not yet described. These included two genes encoding 
transporters, a protein containing leucine rich repeats and an open reading frame 
(ORF) lacking homology to any known or hypothetical protein. Furthermore, the 
previously described MAT-1 (Brodin et al., 1992) encoding the small hydrophilic 
endoplasmic reticulum associated protein (SHERP, Knuepfer et al., 2001) was also 
selected by the SSH technique. Several of these genes were further analyzed, and 
two were expressed for immunization and localization studies. In addition, 
differentially expressed genes were compared by SSH using weakly infective and 
highly infective L. infantum strains.  
 
. 
  36.4 
 Materials and Methods 
 
Parasites 
Two strains of L. infantum strains were used. Promastigotes of the strain LEM 287-
D/ST (low infectivity) and LEM 768-A/ST (high infectivity, Grimm et al., 1991) were 
cultured at 27°C in a 1:1 mixture of SDM-79 (Brun and Schonenberger, 1979) and 
Schneider’s medium (Cunningham, 1977) containing 10% [v/v] heat inactivated 
fetal calf serum (FCS). Parasite densities and parasite volumes were quantified 
with a CASY®1 Cell Counter + Analyser Model TT (Schaerfe System GmbH). 
Cultures were inoculated at a density of 5x105 parasites/ml. Stationary phase 
parasites obtained 15 days (LEM 287) and 10 days (LEM 768) after inoculation 
were used for cDNA SSH. For SSH experiments using logarithmic and stationary 
phase parasites, cultures of the LEM 768 were harvested at different time points 
(table 1).  
 
RNA preparation 
Promastigotes (6ml of an in vitro culture) were centrifuged, the pellet washed in 
phosphate buffered saline (PBS) and total RNA isolated using 10ml TRIZOL 
(Invitrogen). After extraction and isopropanol precipitation, the pellet was 
suspended in 1ml TE (10mM TrisCl pH 8, 0.5mM EDTA). Another 10ml TRIZOL 
was added to the resuspended RNA, RNA extracted, and precipitated again. The 
final RNA pellet was washed with 75% ethanol, suspended in 0.25ml TE. RNA and 
either stored in TE at -80°C or as a precipitate at -20°C. Total RNA (1/100 of the 
preparation) was examined by non-denaturing agarose gel (reference table 1) and 
mRNA was isolated using oligo(dT) cellulose (Micro-Fast Track kit, Invitrogen) 
according to the supplier’s instructions from half the remaining total RNA. 
 
cDNA Subtraction 
Differential cDNA subtraction was performed using the PCR-Select™ cDNA 
Subtraction Kit (Clontech), based on SSH technique (Diatchenko et al., 1996). For 
the strain subtraction, we took advantage of the fact that most trypanosomatids 
mRNAs contain a conserved 5’ region, the spliced leader, first described by 
Boothroyd and Cross (1982). Therefore, we used PCR amplified spliced leader 
cDNA of strain LEM 768 (infective) as tester and cDNA of LEM 287 (low infective) 
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 as driver. Total RNA (~2µg) of both strains was reverse transcribed using 200u M-
MLV reverse transcriptase (Invitrogen) and the RT-primer (table 2). Subsequently, 
RNA was removed by RNase A (Boehringer) digestion. The cDNA was diluted 1:10 
and PCR amplified using the RT-primer and the SL-primer (table 2) according to 
the following program: 25 cycles 30sec 94°C, 30sec 54°C, 2min 72°C using Taq 
DNA polymerase (Qiagen) in presence of 10% [v/v] dimethyl sulfoxide (DMSO). 
These PCR products replaced the double stranded cDNA used in the PCR-
Select™ cDNA Subtraction Kit, whose instructions were followed subsequently. 
For the stage subtraction, ~0.5µg mRNA from late logarithmic phase promastigotes 
(day 2) was used as starting material for the driver and mid-stationary phase 
promastigotes (day 5) as starting material for the tester. The subtraction was 
performed according to the manufacturer’s protocol with a minor modification. After 
the first 2 rounds of subtractive hybridization, the hybridization mix was diluted 
1:200. And instead of using only one dilution as suggested in the kit‘s manual, the 
mix was diluted further (undiluted, 1:10, 1:100) and was amplified in a primary PCR 
(5min 75°C and 27 cycles 30sec 94°C, 30sec 66°C, 1min 30sec 72°C) using 
Advantage® cDNA Polymerase Mix (Clontech). Primary products were diluted 1:10 
and amplified in a nested PCR (5min 94°C and 10 to 28 cycles 30sec 94°C, 30sec 
68°C, 1min 30sec 72°C) using Taq DNA polymerase (Qiagen). For the construction 
of 3 libraries we chose the following PCR products: undiluted hybridization mix with 
16 nested cycles, 1:10 dilution with 19 cycles, 1:100 dilution with 25 cycles. 
The PCR products obtained by both subtraction experiments were cloned into 
pUC18 (Amersham). Several clones were grown for mini prep plasmid 
preparations which were subsequently sequenced. 
 
Northern blot 
RNA was denatured in glyoxal, run on agarose gels after the method of Burnett 
(1997), and transferred to Hybond XL membranes (Amersham) using a vacuum 
blotter (Appligene). For labeling, mini preps were diluted 1:100 and the inserts 
were PCR amplified with SP6 and T7 primers (all primers obtained from Qiagen). 
The products were purified by polyethylene glycol (PEG) precipitation (Hartley and 
Bowen, 1996) and labeled with α-32P dCTP (Amersham) using the High Prime kit 
(Roche Biochemicals). The hybridization was carried out overnight in a 
hybridization oven at 42°C in 1M NaCl, 50mM 4-morpholinepropanesulfonic acid 
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 (MOPS) pH 7, 50% [w/v] formamide, 0.5% [w/v] sodium dodecyl sulfate (SDS), 
1mM EDTA, 18% [w/v] dextran sulfate, 5x Denhardt’s reagent (Denhardt, 1966). 
After hybridization, membranes were washed twice in 2x SSC (1x SSC is 0.15M 
NaCl, 15mM sodium citrate), 0.1% SDS and twice in 0.1x SSC, 0.1% SDS at 42°C. 
The filters were exposed to Kodak MS films for 30min to 48h at -80°C using a 
Transcreen HE enhancer (Kodak).  
 
cDNA walking 
For cDNA walking we also took advantage of the conserved 5’ region in 
trypanosomatids. We chose the strategy shown in figure 1 to obtain full length 
cDNA sequences. mRNA was reverse transcribed by M-MuLV Reverse 
Transcriptase, RNase H- (Finnzymes) using the RT-primer (table 2). RNA was 
removed by RNase A and H digestion. For RT-PCR, the cDNA was diluted 1:50 in 
TE and amplified using insert specific and the RT-primers to obtain the 3’ end, or 
insert specific and the SL-primers (table 2) to obtain the 5’ end. 40 cycles (30s 
94°C, 30s 56°C, 2min 72°C) were performed in Taq buffer in presence or absence 
of 10% [v/v] DMSO using Taq and Pfu (Promega) DNA polymerases in a 10:1 
proportion. PCR products were cloned and sequenced. If no products were 
obtained, a nested PCR was performed to obtain the 5’ end. For primary PCRs, 
outer insert primers and the pSL-primer (table 2) were used, for nested PCRs, 
inner insert primers and the nSL-primer (table 2) were used and 2 x 25 cycles were 
performed. Cycle conditions and the concentrations of DMSO (0-10%), Tween20 
(0-0.5% [v/v]) and BSA (0-0.5g/l) were optimized for each PCR. The primary PCR 
was performed with Taq/Pfu polymerase (10:1), the nested with Taq polymerase 
alone. The PCR products were cloned into pGEM-T (Promega) vector and 
sequenced.  
 
Sequence analysis 
The basic local alignment search tools (Blast) of NCBI 
(http://www.ncbi.nlm.nih.gov/BLAST/, Blastx, Altschul et al., 1990; Gish and States, 
1993) and EBI (Washington University Blast Version 2.0 Parasites, 
http://www.ebi.ac.uk/blast2/parasites.html) were used, transmembrane domains 
were predicted at CBS with TMHMM (Krogh et al., 2001, 
http://www.cbs.dtu.dk/services/TMHMM-2.0/) and motif scans were performed at 
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 EBI with InterProScan (Mulder et al., 2003, 
http://www.ebi.ac.uk/interpro/scan.html). 
 
Protein expression in E. coli 
Proteins were expressed as N-terminal GST fusion proteins with a C-terminal 6 x 
His tag in pGEX-His vector. This vector was obtained by ligation of a His-adaptor 
made by the two oligo-nucleotides His-fw and His-rev (table 2) into SalI- and NotI-
digested (all restriction enzymes obtained from New England Biolabs) pGEX-6p-1 
(Amersham). The following fragments were PCR amplified with primers containing 
a BamHI and SalI site, respectively: the C-terminal part of the putative steroid 
dehydrogenase (clone1, table 3) with primers 1-fw and 1-rev, and a fragment 
between two transmembrane domains of the glucose transporter (clone6) with the 
primers 6-fw and 6-rev (table 2). Prior to ligation, PCR products and the pGEX-His 
vector were cut with BamHI and SalI and purified by phenol extraction and PEG 
precipitation. Proteins were expressed in BL21 cells (Amersham) which were 
grown in Terrific Broth (Tartoff and Hobbs, 1987). When cultures reached an 
optical density of 1, protein expression was induced with 0.5mM isopropyl-β-D-1-
thiogalactopyranoside (IPTG) for 4 hours. All three proteins were insoluble in 
PBS/Triton X-100. Thus, after purification of the inclusion bodies, proteins 1 and 6 
were purified with Ni-NTA Agarose (Qiagen) under denaturing conditions (protein 1 
was not soluble in 8M urea, and urea was replaced with 6M guanidine chloride in 
all solutions).  
 
Immunization 
For each protein, two NMRI mice’s were immunized with 1 and 5µg purified protein 
using CpG DNA as adjuvant (ImmunEasy™ Mouse Adjuvant, Qiagen). Two 
booster injections followed 2 and 4 weeks after the first immunization using the 
same conditions. 6 week after immunization, mice were sacrificed and polyclonal 
sera were collected. 
 
Western blots 
Proteins were run on 12.5% polyacrylamide gels in SDS/glycine buffer and blotted 
semi dry on nitrocellulose (Amersham) in 10mM 3-(cyclohexylamino)-1-
propanesulfonic acid (CAPS), 10% [v/v] methanol, pH10.5. In order to reduce 
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 background and binding of anti-GST antibodies, an extract of induced BL21 cells 
containing the empty pGEX-6p-1 vector was used to adsorb the mouse sera.  
 
Immuno fluorescent assays 
500µl of a 10 day old Leishmania in vitro culture were spun and the pellet was 
resuspended in 20µl Fetal Calf Serum (FCS). 2.5µl each were used to prepare 
several smears on glass slides. Smears were dried, fixed in 1:1 methanol/acetone 
for 10min at -20°C. The slides were partitioned with a hydrophobic pen. E. coli 
adsorbed sera were used at a concentration of 1:20 in PBS, 1% BSA. For 
competition with clone 6, 0.1µg/µl recombinant protein was added, which lead to 
an urea concentration of 0.8M. Therefore, the positive control in this competition 
experiment was done in PBS, 1% BSA, 0.8M urea. Cy3 labeled goat anti-mouse 
IGg antibody (Jackson) was used as secondary antibody 1:200 in PBS, 1% BSA 
and 1ng/µl 4',6-diamidino-2-phenylindole (DAPI) as DNA stain. 
 
 
Results & Discussion 
 
Strain subtraction 
In order to identify Leishmania virulence factors, we subtracted in a preliminary 
experiment cDNA of a strain of low infectivity (LEM 287) from a highly infective 
strain (LEM 768). We used PCR amplified spliced leader cDNA as tester and driver 
for the SSH (figure 2). Northern blot analysis showed that many of the genes 
selected were more strongly expressed by the highly virulent strain than by the low 
virulent strain (figure 3) and that SSH can be used when double stranded cDNA is 
replaced by PCR amplified spliced leader cDNA (obtained from total RNA). This is 
of importance in situations where starting material is limited (for instance for in vivo 
studies). 
Sequence analysis of the genes identified with this first approach made it difficult to 
understand their involvement in virulence as it is unclear why genes such as the 
Histone H1 gene or genes involved in translation elongation should be associated 
with virulence. An explanation for this apparent experimental failure might lay in the 
large difference between both strains, not only seen in infectivity, but also possibly 
in growth rate and other aspects which might be reflected in virulence. 
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 Nevertheless, the histone H1 locus of L. major was also examined by Belli et al. 
(2003) and found to be stage specifically expressed as sense and antisense RNA.  
 
Stage subtraction  
Figure 4 shows the outcome of the SSH. It clearly shows, that the band patterns 
differed, when different dilutions were amplified. This was not suggested in the kit’s 
manual. We also introduced a hybridization control (figure 4) in which the same 
amount of DNA was added prior to PCR, but hybridization was eliminated by 
denaturation (figure 4: - gel). The high background of the undiluted negative control 
was probably caused by amplification of the most abundant tester cDNAs since 
PCR cycling allows hybridization of tester cDNA, which leads to amplification of the 
tester cDNA. Therefore, the background of the undiluted SSH is much higher 
because hybridization is more efficient in concentrated DNA solutions. 
We selected 8 differentially expressed genes from the stage subtraction for which 
the results are shown in table 3. We selected genes which putatively coded for 
proteins involved in transmembrane transport (2 genes), in redox reactions (2 
genes), in protein-protein interactions (1 gene), and 3 genes encoding proteins of 
unknown functions. Recently, extensive work has been published using microarray 
analysis (Saxena et al., 2003) and genes were identified which are expressed at 
higher levels in metacyclics of L. major. These were genes encoding proteins 
involved in cell division, metabolism, membrane transport, protein synthesis and 
other functions. Surprisingly, despite MAT-1 none of the genes described here 
were identified using the microarray technique. 
In order to test whether the identified genes were indeed differentially expressed 
genes, northern blots of selected clones were performed (figure 5). Since double 
stranded DNA was used as probes for northern blots, we cannot determine 
whether we detected sense or antisense RNA. As expected, most of the selected 
genes were up regulated in stat phase cultures, but there was a background of 
constitutively expressed genes, and one clone was even down regulated. This was 
probably due to primer binding sites located within this gene: the adaptors provided 
by the SSH kit are composed of very GC rich sequences, which is also the case for 
the Leishmania genome. Therefore, the background probably increases when 
using the SSH kit for subtractions within GC rich genomes. 
Using Blast searches we found that the inserts of clone 2 and 5 were located within 
  36.10 
 open reading frames (ORFs).  
Clone 5 was identified as a fragment of the previously published metacylogenesis 
associated transcript 1 (MAT-1) which was found several previously by Brodin et 
al. (1992). 
Blast searches with the insert of clone 2, which was down regulated in stat phase 
cultures, showed homologies to CN hydrolases (E-value= 2e-16) and ABC 
transporters (E-value= 2e-11), suggesting its involvement in amino acid (AA) 
transport and/or modification.  
Blast searches to identify the other selected genes initially failed, because of the 
small average size of the inserts (~250bp) and because of their location in the 3’ 
untranslated region (UTR). Therefore we used the strategy depicted in figure 1 to 
obtain the full length sequences.  
A cDNA walk revealed that clone 1 was a sequence fragment of a gene encoding a 
protein involved in redox reactions namely a putative short chain dehydrogenase 
(motifscan: E-value=4.9e-29). 
Clone 3 was identified as a fragment of a gene coding for a putative AA transporter 
(Blastx: AA permease AAP15LD L. donovani, E-value=4e-67), which is up 
regulated in stat-phase cultures. Its sequence differed substantially from the one 
found in L. major metacyclics by Saxena et al. (2003).  
We further identified clone 4 as a gene fragment of a gene containing leucine rich 
repeats, which usually are implicated in protein-protein interactions. This protein is 
homologue to GU1 of T. brucei (Liniger et al., 2001, blastx: E-value=2e-31). 
Clone 6 was found to be a gene fragment coding for a putative sugar permease 
(motif scan: E-value=3.1e-88). There are several glucose transporters known in L. 
mexicana (Burchmore and Landfear, 1998). LmGT1 and 3 are constantly 
expressed during the life cycle, whereas LmGT2 is up regulated in amastigote 
stage parasites. Here we show that expression levels of glucose transporters in the 
different promastigote stages of L. infantum also vary. Mouse sera elicited against 
the selected and recombinamtly produced sugar transporter gave a membrane 
staining in IFAs (figure 6). 
Clone 7 was a fragment of a cytochrome b5 (CYTB5) like gene (motif scan: E-
value=1.2e-15). One could speculate that this protein might be needed for the 
detoxification of oxygen and NO radicals which are present in abundance in 
activated macrophages. 
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 After cDNA walking we obtained for clone 8 a 335 AA ORF but no significant 
homology to any known or hypothetical protein or putative domains could be 
detected therefore the gene function remains unknown. 
 
In order to generate antisera in mice, fragments of the putative short chain 
dehydrogenase (clone 1) and the putative glucose permease (clone 6) were 
expressed in E. coli as GST fusion proteins containing a 6 x His tag. Both proteins 
were found in inclusion bodies, and different expression conditions (change of 
IPTG concentration, expression temperature, or addition of ethanol to induce 
chaperons) did not overcome this.problem. Sera which we obtained for the putative 
short chain dehydrogenase (clone 1) did not recognize the recombinant fragment 
and was excluded from further analysis. Sera against recombinant proteins derived 
from clones 6 showed multiple bands in western blots, despite absorption of sera 
on E. coli extract (data not shown). It might be possible that multiple bands are 
obtained because the different glucose transporter isoforms are highly conserved 
in Leishmania (Burchmore and Landfear, 1998), and therefore might allow cross-
reactivity.  
Immuno fluorescent assays (IFAs) with sera against clone 6 (glucose permease) 
showed a membrane staining, which decreased significantly after competition with 
the recombinant protein (figure 6).  
 
Several genes we found contained transmembrane domains (TM, clones 1, 3 and 
6) and might be localized at the parasite’s surface as integral membrane proteins. 
Such localization for stage specific regulated genes is hardly surprising, since the 
environmental change from the digestive conditions in the insect gut to the harsh 
conditions in phagolysosomes of macrophages certainly requires extensive surface 
changes. And most probably not all membrane proteins will be functional in both 
environments, e.g. pH differences might causes protonization of functional amino 
acids, and thus reduce functional activity. Furthermore, the different environments 
certainly differ in the nutrient supply and these characteristics together may 
explains stage specific gene regulation in genes involved in AA transport, which we 
identified.  
Whether the 3 surface antigens we selected are capable of inducing an 
immunological response, and whether this response has a protective value or 
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 would even enhance infectivity needs to be determined in further studies. In human 
blood, about 90% of the metacyclic forms are killed right after transmission 
(Dominguez et al., 2002). This might indicate that only a small number of parasites 
needs to be eliminated to obtain complete protection. A vaccine might just provide 
that effect and clearance of all metacyclic stage parasites injected by the bite of the 
insect vector might be eliminated.  
 
SSH 
On a technical side it is interesting to note, that inserts derived from the subtraction 
library of different strains and generated by using spliced leader cDNA were 
usually located in the coding region. This facilitated the easy identification of the 
selected genes. In contrast, the stage specific subtraction library contained inserts 
predominantly derived from the 3’UTR and thus required cDNA walking for gene 
identification. For the stage subtraction we used cDNA which was generated by 
reverse transcription with Avian Myeloblastosis Virus reverse transcriptase (AMV-
RT) provided with the subtraction kit. Due to its powerful RNase H activity, AMV-
RT can cleave the template near the 3’ terminus (Kotewicz et al., 1988) resulting in 
cDNA fragments of restricted length. Consequently, most of the inserts in the 
subtraction library were 3' UTR. Further, many of the genes contained long 3’UTRs 
compared to the ORF: 0.1kb 5’UTR, 0.3kb ORF and 1.2kb 3’UTR in case of the 
CYTB5 like gene. Since most of the transcripts are polycistronic in 
trypanosomatids (Graham, 1995), the UTRs are probably strongly involved in 
regulation of the RNA stability hence in stage specific gene regulation. 
 
During the SSH it proved useful to amplify different dilutions of the hybridization 
mix, since some genes were exclusively found in a subtraction library constructed 
by amplification of a distinct dilution, e.g. MAT-1.  
 
Conclusions 
As expected, SSH enriched differentially expressed genes in both subtraction 
experiments. It was furthermore possible to replace double stranded cDNA by PCR 
amplified cDNA, and this expands the use of SSH to experiments, where only 
limited amounts of RNA are available. In one subtraction library (stage 
comparison), most of the inserts were 3’UTR due to the use of a reverse 
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 transcriptase with a powerful RNase H activity. This is not necessarily a drawback 
when working with completely sequenced genomes, but in the case of L. infantum, 
cDNA walking for gene identification was necessary and proved to be difficult and 
time consuming. This could be avoided by replacing AMV-RT by a reverse 
transcriptase lacking RNase H activity, or by using PCR amplified cDNA as starting 
material for SSH. 
From the stage specific subtracted library, we selected 8 differentially expressed 
genes with interesting properties. But in most cases determination of RNA level 
and simple sequence analysis alone were not sufficient to address questions of 
gene function. In order to assign a role of the genes found up regulated in stat 
phase culture, these genes have to be examined in vivo by knock out or RNA 
interference experiments. Furthermore, the biochemical pathways in which the two 
selected enzymes (clones 1 and 7) are implicated have to be determined and the 
suitability of the 3 identified membrane proteins as vaccine candidates has to be 
tested. But in general, SSH is a technique which rapidly allows the identification 
and cloning of stage specifically regulated genes, even for organisms where yet 
micro array expression profiling experiments cannot be done, or micro arrays yet 
are incomplete. While microarray analysis of the L. major transcriptome has been 
performed, none of the genes we selected despite MAT-1 was described in these 
analyses. This might have occurred by chance but might show that microarray 
analyses can overlook other expressed genes. Therefore, classical methods such 
as subtractions still have their value.  
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 Table 1: parasite densities and parasite volumes at different time points 
Days 0 1 1.7 2 3 5 7 
Density 
[counts/ml]  
5x 
105
3.8x 
106
2.8x 
107
5.2x 
107
9.1x 
107
9.9x 
107
9.9x 
107
Mean volume 
[fl] 
24.3 31.5 27.1 21.9 18.9 15.3 13.6 
Volume (max)a 
[fl] 
17.1 26.3 16.3 13.4 12.1 8.1 7.7 
Total RNA Not 
isolat
ed 
Not 
isolat
ed 
 
a) The most frequent cell volume.  
 
Table 2: primers (all obtained from Qiagen). Restriction sites are highlighted. 
Name Sequence Restriction 
site 
RT-primer 5’-ACGACTGTACGTGAATTCGC(T)20 EcoRI 
SL-primer 5’-GCTATATAGAATTCAGTTTCTGTACTTTAT EcoRI 
pSL-primer 5’-AACTAACGCTATATAAGTATC   
nSL-primer 5’-GTATCAGTTTCTGTACTTTATTGAGT   
His-fw 5’- TCGACATCACCATCACCATCACTAGC  
His-rev 5’-GGCCGCTAGTGATGGTGATGGTGATG  
1-fw 5’-AAGATCGGATCCCTGACATCCCTTAACATG BamHI 
1-rev 5’-ATGGCACGTCGACGCTTCGCCTCCATC SalI 
6-fw 5’-ATGGGATCCACGCTGTTTGGCTACAG BamHI 
6-rev 5’-CGGCGAGTCGACCGCTTTCCGACG SalI 
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 Table 3: differential expressed clones. 
Clone Accession 
number 
Expression 
patterna
Sequence used for Blastx and motif scan Most homologous protein  
(Blastx, (Gish and States, 
1993))  
Motifs (Krogh et al., 2001; Mulder et al., 
2003) 
1   + 1.7kb cDNA including complete ORF hypothetical protein C56G2.6 
Caenorhabditis elegans 
E=3e-31 
2 TM domains, NAD(P) binding Rossmann-
fold domains E=3e-40 (Rossmann et al., 
1975), short chain dehydrogenase (Benyajati 
et al., 1981; Jornvall et al., 1995) E=4.9e-29, 
glucose/ribitol dehydrogenase E=2.5e-15 
2   --- 510bp insert of SSH library putative amidohydrolase
Neurospora crassa E=2e-17 
 Nitrilase/N-carbamoyl-D-AA amidohydrolase 
E=2.4e-20 (Bork and Koonin, 1994), 
P-loop containing nucleotide triphosphate 
hydrolase E=4.6e-12, 
carbon-nitrogen hydrolase E=1.8e-5 
3   ++ 1.8kb 5’end of cDNA AA permease AAP15LD L. 
donovani E=4e-67 
8 TM domains,  TM AA transporter protein 
E=1.2e-6, aromatic AA permease II (Weber 
et al., 1988) 
 
4   ++ 777bp 5’ and 754bp 3’end of cDNA, 
assembled with L. major Friedlin 
chromosome 31 (AL499621.2) P=1.8e-
133 (5’) and P=9.5e-105 (3’) 
GU1 Trypanosoma  brucei 
(Liniger et al., 2001) 
E=2e-31 
leucine rich repeats (Kobe and Deisenhofer, 
1994) 
5   +++ 534bp cDNA including complete ORF Mat-1 protein L. infantum 
(Marin et al., 2000) (Knuepfer 
et al., 2001) E=2e-41 
none 
6   + 845bp 5’ and 950bp 3’ end of cDNA, 
assembled with L. major Friedlin 
chromosome 36 (AL499624.2) P=4.1e-
142 (5’) and P=5.9e-181 (3’) 
LmGT2 or 3 L. mexicana 
(Burchmore and Landfear, 
1998) for both E=0.0 
11-12 TM domains, general substrate 
transporter E=1.5e-105, sugar transporter 
E=3.1e-88 (Mueckler et al., 1985) 
7   ++ 975bp 5’end of cDNA including complete 
ORF 
CG2140-PB (CYTB5) 
Drosophila melanogaster  
E=8e-8 
CYTB5 family E=1.2e-15 (Abe et al., 1985; 
Ozols, 1989), heme/steroid binding domain 
E=2e-6. 
8   ++ 1.9kb cDNA including complete ORF none none 
a) +: up regulated in stat phase cultures, -: down regulated. 
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 Figures 
 
 
Figure 1: Most mRNAs in Leishmania contain a conserved spliced leader (SL) at the 5’ end. 
Therefore, PCR was used for obtaining the full length cDNA sequence. 
 
 
 
Figure 2: The starting material used for the strain subtraction. M: DNA marker; 1-4: SL-cDNA; 1,2: 
strain LEM 278; 3,4: strain LEM 768; 1,3: uncut; 2,4 Rsa I cut. 
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Figure 3: Northern blot analysis of 3 clones of the strain subtraction library. A: RNA confirming equal 
loading; B: zinc finger (DHHC type) family protein (BLAST: E=3e-7); C: not identified sequence; D: 
translation elongation factor α; 2: RNA of strain LEM 278, 7: RNA of strain LEM 768. 
 
 
 
Figure 4: Effect of dilution and number of nested cycles to the outcome of the suppression 
subtractive hybridization. In the lower gel (-), the hybridization mix was denatured prior to the PCR 
in contrast to the upper (+) gel.  
  36.21 
  
 
Figure 5: Northern blot analysis of 6 different clones. Left image: RNA gel confirming equal loading 
(with the 3 ribosomal bands typical for trypanosomatides); right image: northern blot. A: clone 1 
(dehydrogenase); B: clone 3 (amino acid permease); C: clone 5 (MAT-1); D: clone 6 (GT 2?); E: 
clone 7 (cyt b5?); F: clone 4; M: 1kb DNA ladder (Invitrogen, DNA and RNA run +/- equal when 
treated with DMSO/glyoxal); 1: RNA of day 1.7; 2: RNA of day 2; 5: RNA of day 5 cultures. 
 
 
 
Figure 6: IFAs using sera against a putative glucose transporter (clone 6). A: serum mediated 
membrane staining, B: DAPI and bright field of the same region, C: competition with 0.1µg/µl 
recombinant protein, D same exposure time as C without recombinant protein. 
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 4.4. Additional Methods and Results 
 
The low quality cDNA obtained after 1st and 2nd strand 
synthesis when the enzymes provided with the subtraction 
kit were used is shown in figure 7, where it is compared to 
ds cDNA obtained after reverse transcription using M-MLV 
RT, RNase H and 2nd strand synthesis following a 
standard protocol (using RNase H, E. coli DNA 
polymerase I and E. coli DNA ligase at the same time, 
described in Sambrook and Russel, 2001) 
Figure 7: 
comparison of 
different ds cDNA 
preparations 
 
Figure 8 shows glyoxal Northern blots 
using clone 2 and 8, which are not 
shown in the publication above. 
Furthermore, for some clones virtual 
Northern blots were performed in order 
to save RNA. For that, RNA was 
replaced by amplified SL cDNA (see 
appendix 2) and blotted after Southern 
blot standard procedures. Figure 9 
shows a comparison of virtual Northern, 
formaldehyde Northern, and glyoxal 
Northern blots of clone 3. It is not 
surprising, that the cDNA size indicated 
by the band on the virtual Northern is 
much smaller, since cDNA walking 
revealed the ability of this particular cDNA 
to recombine during PCR amplification 
(figure 10). The walk had to be performed 
in a total of 3 steps and after sequencing it 
was clear, that most of the bands indeed 
derived from the expected DNA but they 
obtained central deletions of different 
sizes (amplification of the cDNA belonging 
to clone 4 resulted in similar observations). 
 
 
 Figure 8: Northern blot analysis of 
the down regulation of clone 2 and 
up regulation of clone 8. The number
above the lanes represent the age of
the in vitro culture.Figure 9: formaldehyde, glyoxal and 
virtual Northern of clone 3.  37
  
 
 
Figure 10: PCR products obtained by cDNA walking of clone 3 using different primers (A, 
B) and annealing temperatures. To the right: a deletion in the most prominent band when 
using primer A. It resulted from recombination during PCR. 
Nevertheless, the expression pattern shown in the virtual Northern blot once 
more proved the quality of the amplified SL cDNA for many applications. 
 
 
Three proteins were recombinantly expressed in E. coli: clone 1 encoding a 
putative short chain dehydrogenase, clone 5 representing MAT-1 and clone 6 
encoding a putative glucose transporter. Figure 11 shows total cell lysates of 
the expression clones and purified proteins.  
 
Figure 11: Expression of 3 Leishmania proteins in E. coli. A: E. coli lysate; M: marker, 37, 25: 
expression temperature; 0:  no induction; 1, 6, 5: clone 1, 6, 5. B: purified protein of clone 5; 
FT: flow through, E: elution. C,D: purified protein of  clone 1 and 6. 
 
MAT-1 (clone 5) encodes the SHER protein, which was described by 
Knuepfer et al. (2001). In order to access the localization of this protein, the 
protein was expressed in E. coli in order to perform IFAs. 
cDNA encoding the N-terminal part was amplified using the primers 5’-
TTGGGATCCATGATTATCCGCTATATGTC and 5’-
GAGAGAGTCGACGAAAAGGGAGAGAAGAG, cut with Bam HI and Sal I and 
ligated into the pGEX-His vector (appendix 6.A10). As described by Marin et 
al. (2000), the protein showed to be toxic for E. coli leading to frame shifts and 
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 preliminary stop codons, which resulted in products of restricted length. 
Consequently, the C-terminal His-tag was deleted in the recombinant protein. 
While expressed at high levels, the protein showed to be highly insoluble, and 
it was finally purified at mild denaturing conditions using sarkosyl and 
glutathione sepharose after the method of Frangioni and Neel (1993), 
appendix 6.A12) with low yield. Previously, several different renaturation 
protocols were tested without success for proteins in inclusion bodies which 
were dissolved in urea or guanidine chloride. Polyclonal sera against the 
protein recognized several bands in Western blots using total protein of 
Leishmania promastigotes. However, there was a cytoplasmatic structure 
stained in IFAs (figure 12). Using light microscopes of higher resolution and 
TEM, Knuepfer et al. (2001) showed that this protein is associated with the 
ER. 
 
 
 
A       B 
 
 
C       D 
 
 
 
 
Figure 12: A: IFAs using a polyclonal serum against recombinant SHERP. B, D: DAPI stain 
and bright field of the same region. C: merge of A and B. 
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 4.5. Discussion 
 
 
4.5.1. Choice of the approach 
 
We tried to identify potential virulence factors using cDNA subtraction. In our 
first experiment, we subtracted cDNA of an avirulent from a virulent strain. 
The selected genes would therefore have a direct link to virulence. 
Unfortunately, the difference of two strains was not only drawn by virulence, 
but also by other aspects. Therefore, equation of the genes selected by the 
subtraction with potential virulence factors was not possible. 
Thus, we then subtracted stages of the same strain differing in virulence.  The 
latter approach had the disadvantage that there usually are many stage 
specific expressed genes, but only a few of them are involved in virulence. 
Therefore, a direct connection between selected genes and virulence lacked. 
We selected 3 differentially expressed genes which most probably are 
involved in nutrient transport. Without further experiments, it was not 
distinguishable whether these genes are stage specific regulated or 
induced/repressed by changes in nutrient concentration. In vitro cultivation 
was done without changing the medium; therefore, the nutrient concentration 
differed substantial with the age of the culture. However, many researchers 
believe that genes are regulated rather by fixed programs in, what they call 
lower eukaryotes as by changes in the environment. 
Nevertheless, due to the fact that MAT-1, a gene known to be metacyclic 
specific, was selected by the subtraction proved the selectivity of the 
technique, considers our approach as successful. However, we cannot claim 
to have identified only virulence associated genes 
 
 
4.5.2. Choice of the technique 
 
Several methods exist for detection of differentially expressed genes: many 
subtraction techniques, differential display or DNA microarray analysis. The 
latter approach is only possible, when the genome of the organism of interest 
is (almost) sequenced, and usually yields huge amount of data. Since at the 
beginning of this project the sequencing of L. majors’ genome was in its 
infancy the application of this method was not feasible. However, it is 
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 interesting to note that, beside MAT-1, none of the genes we selected using 
SSH was found by micro analysis by Saxena et al. (2003). Whether this is due 
to chance, or whether it shows that, despite a large amount of generated data, 
microarray analyses miss a lot of differentially regulated genes is unclear. 
Furthermore, microarrays will fail to detect RNA editing and alternative 
splicing, which has been described for more and more genes (however as 
known so far, introns are very rare in trypanosomatids). 
Compared to conventional subtraction methods, SSH is an advanced 
technique, because it incorporates normalization during the first round of 
subtraction. The method therefore yields fragments of both, abundant and low 
abundant, differentially expressed RNA. Thus, SSH was the method of choice 
in our experiments.  
However, a RNA species becoming more and more important will be missed 
by all techniques mentioned above: micro RNAs (miRNAs). These usually 
about 22nt long miRNAs are missed during reverse transcription (e.g. using 
oligo-dT derived primers) and further, in microarray analysis, because of their 
restricted length yielding in low melting points (the spotted fragments in micro 
array usually are 50nt to several 100nt long). Nevertheless, miRNA are highly 
abundant in both, prokaryotes and eukaryotes, and are involved in as 
important features as gene repression, regulation of RNA stability and both, 
translational repression and activation (reviewed by Bartel, 2004). 
 
The objective was to identify potential virulence factors, drug targets and 
vaccine candidates. Whether the genes we have selected by cDNA 
subtraction fulfil this objective cannot yet be determined. However, some of 
the selected genes show interesting properties: the gene encoding domains 
involved in protein-protein interactions (a homologue protein with unknown 
function has been described in the pathogen T. brucei brucei) and the gene 
encoding a protein lacking any domains and homologies to known or 
hypothetical proteins as examples. 
In our subtraction, the slowest step surely was the identification of the 
selected genes. Therefore, many more genes might have been selected and 
identified if the subtraction was repeated using a reverse transcriptase lacking 
RNase H activity or when we would have managed to get to work the 
modifications of SSH described chapter 4.2.  
In order to perform localization experiments three of the selected genes were 
expressed recombinantly in E. coli. Immunization with clone 1 did not result in 
useful sera and the localization of MAT-1 encoding SHERP was previously 
described. In IFAs, antibodies against clone 6 stained the parasite’s surface; 
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 this confirmed the sequence analysis, which showed that this clone encoded 
a glucose transporter.  
Alternatively, instead of immunization experiments, gene overexpression or 
knock outs could have been performed in transformation experiments. Since 
there was no experience in our group on Leishmania transformation, this 
would have been a high risk project. Whether such an approach would be 
able to define the effect of this particular gene on virulence remains to be 
shown. All together it seems that the chosen methods were appropriate within 
reasonable costs, but modification might yield more results. 
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 5. General Discussion 
 
Although the three projects can be merged only loosely under the term 
leishmaniasis, there is a molecular link between them: the mini-exon gene 
encoding the spliced leader. The gene itself was used as template for the 
diagnostic PCR, spliced leader cDNA was used to construct expression and 
subtraction libraries and it enabled cDNA walking for identification of genes 
selected in subtractions. 
Histones represent another tie between the subtraction experiment and the 
serum screen: core histones showed to be of diagnostic value, and histone 
H1 was higher expressed in metacyclics of the more virulent Leishmania 
strain. The interesting properties of Leishmania histones (unusual high 
diversity and differential expression in strains differing in infectivity) might 
indicate the presence of a goldmine for understanding these parasites. 
The three projects were performed in order to develop tools for diagnosis of 
human and canine leishmaniasis, and for identification of vaccine candidates 
and potential virulence factors. 
 
 
5.1. Diagnosis 
 
A PCR assay allowing diagnosis and species differentiation of Leishmania 
species causing human leishmaniasis was not yet available. Therefore, we 
developed a mini-exon PCR which exactly fits into this missing field. While the 
PCR and RFLP assay now is routine use at the STI showing satisfying 
results, distinguishing between Viannia species still remains a challenge. 
Since the required treatment of species belonging to this subgenus differs 
substantially, this is a major draw back. However, the assay might be able to 
be improved: restriction digests show only different patterns, if mutations are 
present within the recognition sequences of the selected enzymes. This 
problem could be overcome with chip technology, which then could facilitate 
the differentiation of Viannia species, or by using an additional genetic 
marker. 
 
While many different diagnostic tools are available for canine leishmaniasis, a 
diagnostic test capable of detection of early stages of infection is still lacking. 
We selected a few promising antigens suitable for an early diagnostic test for 
canine leishmaniasis. However, Leishmania histones have been previously 
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 described as antigens, inducing strong humoral responses in both, infected 
dogs and humans. Whether the epitopes we selected incorporated better 
properties has to be tested using sera of many more naturally and artificially 
infected dogs. Since we used cDNA derived from a highly infective and 
virulent strain for the serum screen, the epitopes we identified might be good 
candidates. Collaboration with a laboratory in Spain will provide this 
information. 
However, the goal of an early diagnostic test for canine leishmaniasis was to 
allow mass diagnosis and treatment street dogs as a control tool for 
leishmaniasis in Southern Europe. Whether this dodgy approach will succeed, 
has to be shown in future. It surely will be intensive in costs and work and will 
not protect treated dogs from relapses and re-infection. Furthermore, the 
consequences in respect to drug resistance might be fatal. Therefore, it 
seems that it would be more feasible to concentrate all means on the 
development of a vaccine for both, humans and dogs, and for development of 
new drugs. Nevertheless, an early diagnostic test for canine leishmaniasis 
would be an improvement of veterinarian praxis. 
 
 
5.2. Vaccine candidates 
 
By enriching metacyclic stage specific genes, we also enriched for potential 
transmission blocking vaccine candidates. Several integral membrane 
proteins were selected, two transporters and a dehydrogenase. Whether 
these proteins are suitable as vaccine candidates has to be shown in future 
studies. Here fore, they must be able to induce a long lasting protective TH1 
type immune answer, and must be stable and produced cheaply to allow 
mass treatment. Although the probability whether these conditions are fulfilled 
by one of the three proteins we selected is rather low, the immense value of a 
vaccine as a powerful tool for control of leishmaniasis justifies a slight hope. 
Nevertheless, the enrichment of potential vaccine candidates was only a 
byproduct of a subtraction designed for the selection of potential virulence 
factors. 
An alternative to designing a vaccine based on single or several parasites’ 
molecules is to develop live or killed vaccines. However, costs for Leishmania 
cultivation currently are much too high. By lowering these costs, (e.g. 
achieving serum-free cultivation in a cheap medium), the use of attenuated 
parasites would be a true alternative. Furthermore, cultivated parasites are 
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 not only worthwhile as vaccine but are also of excellent diagnostic value. 
 
 
 
5.3. Virulence factors 
 
Classically, virulence factors have been defined as factors causing or 
enhancing the severity of a disease. However, the distinction of virulence 
factors (causes for pathology) from factors involved in pathogenicity appears 
to be artificial. Thus, all parasite factors enabling/enhancing the parasite’s 
infectivity, survival within the host and factors defining the severity of the 
disease could be handled as virulence factors. Understanding the mode of 
action of these factors is crucial for understanding leishmaniasis. 
We performed two experiments in order to enrich potential virulence factors. 
However, whether the selected genes are involved in virulence has to be 
shown using in vivo studies. Due to the complexity of the matter, assigning 
the role of virulence factors as well as their mode of action is a challenge, as 
the example of LPG shows. Although LPG was suspected to be a virulence 
factor many years ago, its impact was unclear or misunderstood. Since initial 
findings showed that LPG enhances the metacyclic’s resistance to the 
complement and is involved in the transient inhibition of phagolysosomal 
fusion, these properties were believed to be the mode of action. However, 
using lpg- mutants, Spath et al. (2003) showed that at least in mice, 
complement mediated lysis is an ineffective way of controlling the disease. 
Lpg- metacyclics were opsonised by complement factors and entered 
macrophages. They also showed that inhibition of phagolysosomal fusion is 
not essential for the parasite’s survival within phagocytes. Nevertheless, lpg- 
mutants showed a significant higher sensitivity to oxidative stress, decreasing 
the parasite’s ability to resist the oxidative burst generated by activated 
macrophages. The different observations and conclusions on LPG’s impact 
were most probably derived from using different approaches: the initial 
experiments were performed in vitro and using biochemical methods (LPG 
shares domains with many other Leishmania derived molecules). The 
example of LPG clearly shows, that defining a gene as virulence factor is 
intricate: although recent studies confirm that LPG is involved in virulence, this 
could in principle have been disproved just as well. 
Furthermore, the results of in vivo studies using mice cannot be directly 
assigned to humans, due to significant differences in the immune system. 
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 Therefore, much care has to be taken when defining virulence factors, since 
the outcome of experiments depends on the approach, technique and system 
used. 
These facts clearly show that identification of virulence factors would be far 
beyond the reach of this PhD project. Nevertheless, our experiments were 
designed to select for potential virulence factors. The selected genes were 
expressed at higher levels in the more infective strain or in the infective 
parasite stage respectively, which is a first indication, that they could be 
involved in virulence. 
 
 
5.4. Drug targets 
 
Gene products expressed in metacyclic and amastigote parasites are 
potential drug targets for prophylaxis and/or treatment, if they are essential for 
the parasite and differ in the tertiary structure from homologues expressed in 
the host. Therefore, we enriched also potential drug targets by the cDNA 
subtraction. However, since expression in amastigotes was not yet shown, the 
use of these genes might be of limited value as drug targets. Nevertheless, 
some of the genes, such as the GU1 like gene, have no homologies at all to 
mammalian proteins known so far (at least in the primary structure). 
There are some newer antileishmanial drugs in use and in the pipeline, but 
their number is restricted, and most of them are no oral agents. In order to 
avoid progression of drug resistance (which already has spread widely to 
antimonials), alternative drugs are highly welcome. By using several different 
drugs at different locations and time points, progression of resistance might 
be successfully suppressed and even reversed. However, in addition to 
evolution-driven selection of resistant phenotypes, Leishmania parasites can 
react unspecifically to drug pressure by gene amplification yielding in 
extrachromosomal plasmids and mini chromosomes. Nevertheless, some 
chemical and physical properties of a drug can aggravate the development of 
resistances:  
1. A rapid mechanism of action, as observed by the antimalarial 
artemether, prevents unspecific adaptations of the parasite such as 
gene amplification. However, drug resistance can still progress by 
selection of resistant phenotypes formed by chance in the whole 
parasite population. 
2. It is more difficult for the parasite to develop resistance to drugs which 
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 don’t need parasite’s transporter molecules to reach the point of action. 
These are either drugs damaging the parasite surface or hydrophobic 
molecules which are able to diffuse through biological membranes. 
However, against the latter drugs, an effective countermeasure is 
active transport out of the parasites cytosol. 
Development of antileishmanials surely is a challenge: Leishmania is endemic 
in poor regions of the world, therefore production should be of low costs and 
oral application should be possible (in order to lower treatment costs). 
Furthermore, the drug should exhibit low rates of adverse reactions. The fact 
that toxic antimonials still are widely used clearly shows the deficits of today’s 
antileishmanials. The property of Leishmania parasites to multiply within 
acidic compartments might be utilized by the drug development: hydrophobic 
molecules, which are uncharged at neutral pH but protonated within 
phagolysosomes are able to diffuse through membranes when they are 
uncharged. Once protonated, membrane diffusion is disabled. This leads to 
accumulation of high drug concentrations within phagolysosomes, which 
might enhances the efficiency of the drug concurrent with reduction of 
adverse reactions. 
However, it is more likely that new drugs are identified by screening of 
thousands of compounds than by specific design upon potential drug targets. 
The selected drugs then could be chemically modified using the criteria 
mentioned above. Nevertheless, some parasite specific proteins without 
mammal homologues might ask for direct design of drugs. Whether the GU1 
homologue we identified or other genes selected by cDNA subtraction qualify 
for this purpose cannot yet be answered. 
 
However, the cDNA subtraction experiments proved their ability to select 
genes exhibiting interesting properties not only in respect to potential 
virulence factors, but also to potential transmission blocking vaccine 
candidates and to potential drug targets. However, it has to be straightened 
out that these preliminary results are far from practical application, they only 
exhibit indications that further research on some genes we identified might 
yield in powerful tools for control of Leishmania. 
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 6. Appendices 
 
6.A1. Hybridization buffers for Northern blot analysis 
 
 Buffer A Buffer B 
SSPE pH 7.2 5x - 
MOPS pH 7.0 - 50mM 
NaCl - 1M 
Form amide 50% [w/v] 50% [w/v] 
SDS 0.5% [w/v] 0.5% [w/v] 
Dextran sulfate 8% [w/v] 15% [w/v] 
Denhardt’s reagent 5x 5x 
 
Hybridization temperature: 42°C for both buffers 
 
Buffer A was more stable but less sensitive than 
buffer B. This was most probably due to the fact, 
that it contained less dextran sulfate yielding in 
lower viscosity (the higher the viscosity, the 
higher the sensitivity especially when using 
double stranded probes). Addition of more 
dextran sulfate resulted in an insoluble precipitate 
most probably mediated by the phosphate buffer 
(many phosphates are insoluble). Therefore, the 
phosphate buffer was replaced by MOPS in buffer 
B. 
 
Ingredients 
• Dextran sulfate was clearly the better choice for raising the viscosity 
compared to PEG (figure).  
• The Na+ concentration of approximately 1M of both buffers is optimal for 
hybridizations 
• Form amide reduces the melting point of nucleic acids and discriminates 
DNA-DNA base pairs compared to RNA-DNA base pairs. 
• SDS lowers the surface tension. 
• Denhardt’s reagent is used to block the membrane. 
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 6.A2. Construction of spliced leader cDNA 
 
Primers:         Eco RI 
1str Eco primer      5’-CGACTGTACGTGAATTCGC(T)20
SL Eco primer 5’- GCTATATAAGAATTCAGTTTCTGTACTTTATTG 
 
Reverse Transcription 
1 To 1.5µg total or mRNA add 14µl 10µM 1str Eco primer and TE to 23.5µl final 
volume. 
2 Incubate 5min @ 70°C, snap cool, quick spin. 
3 Add  3µl 10x 1st strand buffer, 
1.5µl 10mM dNTPs, 
0.5µl RNasin (Invitrogen) 
1.5µl M-MLV RT, RNase H- (Finnzymes) 
4 Incubate 1hour @ 37°C. 
When total RNA was used:     
5 Heat inactivate RT for 2min @ 95°C. 
6 Quickspin, add 1µl RNase A (1g/l) and incubate 15min @ 37°C. Store @ -
20°C. 
When mRNA was used: 
5 Add  22.7µl H2O  
6µl 10x RNase H buffer  
1µl RNase A (1g/l) 
   0.3µl RNase H (5U/µl) 
6 Incubate 20min @ 37°C. Store @ -20°C and use a 1/10 dilution in TE as PCR 
template. 
 
PCR 
1 Prepare a mastermix containing 1x Taq buffer (1.5mM MgCl2), 10% DMSO, 
0.2mM dNTPs, 0.5µM SL Eco and 1str Eco primer, and use Taq:Pfu DNA 
polymerase in a 8:1 proportion.  
2 Add 1-2µl 1st strand cDNA for a 50µl reaction. 
3 Perform 20-35 cycles at the following conditions 
  30sec 94°C 
  30sec 54°C 
  2min 72°C 
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 6.A3. Isolation of genomic Leishmania DNA 
 
Cells are lysed in SDS, proteins are digested by proteinase K and extracted with 
phenol 
 
From in vitro cultures   
1 Centrifuge culture 5min @ 1’500g. 
2 Wash the cells in PBS. 
 
From biopsy 
1 Store specimen in 0.9% NaCl @ -20°C.  
2 Thaw material quickly. 
 
 
3 Resuspend in proteinase K buffer (10mM TrisCl pH8, 5mM EDTA, 0.5% SDS) 
culture: 108 cells/ml, biopsy: depends on the size of specimen, ~500µl. 
4 Add proteinase K to a final concentration of 0.5g/l. 
5 Incubate 3 hours to overnight @ 56°C. 
6 Extract the aqueous phase once with 1 volume phenol (pH 8), once with 1 
volume phenol/chlorophorme, and once with 1 volume chlorophorme.  
7 Ethanol precipitate the DNA using 1/10 volume of 3M NaAcetate (pH 5.2) and 
2-3 volumes of EtOH abs. 
8 Incubate 30min @ RT. 
9 Spin 30min @ full speed. 
10 Wash the pellet in 75% EtOH. 
11 Resuspend the DNA in 50-100µl TE (10mM TrisCl, pH 8, 0.5mM EDTA). 
12 Optional: add RNase A to a final concentration of 10mg/l. 
13 Store @ -20°C. 
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 6.A4. Selective DNA precipitation using PEG  
Modified from Hartley and Bowen (1996) 
 
Vol PEG     2.5   1.5    1    3/4  2/3  0.6  0.55
% PEG            14     12     10    8.6     8     7.5    7.1 
3kb 
Size 
2kb 
1.6kb 
1kb 
517 
506 
396 
344 
298 
220 
201 
154 
134 
 
Figure: 0.5µg 1kb DNA ladder (2.5µg/ml in TE) was precipitated by addition of 0.55 to 2.5 
volumes PEG 8000. The samples were incubated 10minn @ RT and spun 30min @ 
16’000g and RT. The pellets were washed in 75% EtOH and resuspended in TE. 
 
 
Protocol 
 
1. Add 0.5 to 2.5 volumes1, 2) of PEG stock (20% PEG 8000, 1M NaCl) to 1 
volume DNA solution. 
2. Incubate 10min @ RT 
3. Spin 30min @ 15’000g3) and RT. 
4. Wash pellet in 75% EtOH. 
5. Resuspend in whatever you need it. 
 
1) For purification of PCR products: 1vol PEG (>400bp), 1.5vol PEG (200-400bp). 
2) PEG precipitation is DNA concentration dependent: try different amounts if you 
need it exactly.   
3) No significant loss was observed by spinning a 96 well plate 60min @ 4’000g. 
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 6.A5. Sequencing of GC-rich DNA 
 
 
1. Denature the template dissolved in H2O for 5min at 95°C 
2. Add the sequencing primer and TRR (Perkin Elmer). 
3. Perform 30 cycles at the following conditions: 
5sec 98°C 
  90sec 60°C 
  90sec 50°C 
4.  Follow the standard protocol 
 
 
 
 
6.A6. Sequencing of large inserts 
 
 
Find one or several polylinker 
restriction enzyme cutting within 
the insert sequence. 
 
 
 
After cutting and religation, the 
plasmid obtains a deletion. 
Sequencing using vector primers 
results in a sequence starting 
centrally within the primary insert. 
 
 
 
 
Sequence assembly reveals the 
complete insert sequence. 
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 6.A7. Cycle restriction ligation (CRL) 
After Pusch C, Schmitt H, Blin N. Increased cloning efficiency by cycle 
restriction-ligation (CRL) Technical Tips Online, 1: T40071 
 
Here, ligation is performed in the presence of a polylinker restriction enzyme: 
whenever the vector is recirculated without insert, the restriction enzyme will cut it 
again. When an insert is ligated into the vector, the restriction site is destroyed. 
This protocol uses Sma I (recognition sequence CCC▼GGG, blunt end cutter). 
Addition of K+ in this protocol is required for activity of Sma I. If you use a different 
restriction enzyme (e.g presence of a Sma I site within your insert, or your insert 
starts with sequence 5’-CCC, etc), make sure that it is active in the ligation buffer. 
 
Prepare on ice: 
• 1µl 10x T4 ligation buffer containing ATP 
• 1ul 50% PEG8000 
• 0.5µl 0.1M KCl 
• 0.5µl 0.1M DTT 
• x µl vector DNA (uncut) 
• y µl insert DNA 
• 1µl 10u/ml Sma I 
• 1µl T4 DNA ligase 
• dH2O to 10µl 
 
Place in a thermocycler and run the following program: 
  ______ 
20min 25°C  } 
           } 
  1min 10°C } } 
30sec 22°C } 6x } 20x 
   } 
30sec   4°C  } 
30sec 30°C ______} 
 
1h 25°C 
15min 65°C 
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 6.A8. Small scale preparation of electro-competent cells 
 
 
1. Thaw a glycerol stocks of any overnight culture, which was not overgrown too 
heavily. 
2. Spin the culture and discard the supernatant. 
3. Wash the pellet 2 times in 1ml ice-cold dH2O. 
4. Resuspend the pellet(s) in 50µl ice-cold dH2O. 
 
The cells are now ready for electroporation. Do NOT freeze them, only for immediate 
use! 
 
 
6.A9. E. coli transformation 
Based on Inoue et al. (1990) 
 
Media and buffers  
SOB medium: 
20g/l bacto tryptone 
  5g/l yeast extract 
  0.5g/l NaCl 
  0.19g/l KCl 
Autoclave. 
Just before use add MgCl2 to 10mM end concentration (SOB agar plates: 20mM) 
from an autoclaved 2M stock. 
 
SOC medium: 
Add 2% filter sterilized 1M glucose to SOB (20mM end concentration). 
 
ITB (Inoue transformation buffer) 
1. Dissolve   
  10mM HEPES or PIPES, 
  15mM CaCl2, 
250mM KCl  
in dH2O. 
2. Adjust pH to 6.7 with KOH. 
3. Add MnCl2 to 55mM. 
4. Sterilize with a 0.45µm filter and store @ 4°C. 
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Preparation of competent cells 
 
1. Inoculate 200ml SOB with about 10 large colonies. 
? For best results pick colonies from a freshly grown plate. Use different 
amounts for inoculation to have one culture at the desired density the 
next day. 
2. Incubate for about 20 hours at RT (best: 18-22°C) with vigorous shaking (200-
250rpm) until OD600=0.45  
? OD=0.3-0.55 works well. 
3. Place the culture on ice for 10min. 
4. Spin 10min @ 2’500g and 4°C.  
5. Resuspend the pellet in 64ml ice cold ITB, incubate 10min on ice and spin 
again. 
6. Resuspend the cells in 16ml ice cold ITB. 
7. Slowly add 1.2ml DMSO while gently swirling and incubate 10min on ice. 
8. Dispense the suspension into 0.2–1ml aliquots, immediately freeze by 
immersion into liquid N2. Store @ -80°C. 
9. Thaw an aliquot for testing your cells (pos AND neg!).  
? Expect 108–109 transformants/µg supercoiled plasmid in DH5α. 
 
 
Transformation 
 
1. Thaw cells @ RT and immediately transfer on ice. 
2. Add 50-100µl cells to your DNA (the volume of the DNA should not exceed 
5%). 
It is not necessary to precipitate a ligation mix prior to transformation. 
3. Incubate on ice for 15min. 
4. Heat shock 1min @ 42°C in a water bath, cool in ice water. 
? Alternatively, you can plate the transformation mix directly on 
prewarmed plates. 
5. Add 900ml SOC, incubate 30min @ 37°C and plate the bacteria. 
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 6.A10. Modified expression vectors 
 
 
λgt11-His 
 
Modification 
Addition of 6xHis adaptors in 3 reading frames into the Eco RI site of λgt11. 
 
Use 
Cnstruction of cDNA expression libraries. The His tag allows recognition of the 
expressed lacZ fusion proteins by anti-His antibodies and facilitates the protein 
purification after the inserts are subcloned into an expression plasmid. 
 
 
 
Construction of the vector 
The adaptors containing a 5’ phosphorylated Eco RI and a 3’ Nla III overhang (figure) 
were ligated to Eco RI cut and dephosphorylated λgt11 DNA (Pharmacia). All three 
adaptors at a concentration of 1µM each were ligated to 0.5µg λ arms in 10µl 
reaction volume. The DNA was purified by phenol extraction, ethanol and PEG 
precipitation. 
 
Sequencing primers 
See figure. 
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 pGEX-His 
 
Modification 
Addition of a 6xHis tag at the C-terminus of the GST fusion protein. 
 
Use 
Expression and purification of full length fusion proteins containing an N-terminal 
GST and a C-terminal 6xHis tag. 
 
 (27-4597-01)
EcoR I Sma I Sal I Xho I Not IBamH I
PreScission ™ Protease
Leu  Glu   Val   Leu   Phe  Gln   Gly   Pro   Leu   Gly   Ser   Pro   Glu   Phe  Pro   Gly   Arg   Leu   Glu   Arg   Pro   His
CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCC CCG GAA TTC CCG GGT CGA CTC GAG CGG CCG CAT
pGEX
~4900 bp
pBR322
ori
Bal I
BspM I 
Ptac g
lut
ath
ion
eS-
trans
ferase
Am
p r
lac I q
Nar I
EcoR V 
BssH II 
BstE II 
Mlu I
Apa I 
Tth111 I 
Aat II 
Pst I
p4.5
AlwN I  
pSj10  Bam7Stop7
 
EcoR I Sma I Sal IBamH I
PreScission ™ Protease
Leu   Glu  Val   Leu   Phe   Gln  Gly   Pro   Leu   Gly  Ser    Pro   Glu   Phe   Pro   Gly   Arg  His   His   His   His   His   His  stop   
CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCC CCG GAA TTC CCG GGT CGA CAT CAC CAT CAC CAT CAC TAG CGG CCG CAT
Not I
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 Construction of the vector 
The adaptor obtained by annealing the two oligos 5’-
AATTCCCGGGTCGACATCACCATCACCATCACTAGC and 5’-
GGCCGCTAGTGATGGTGATGGTGATGTCGACCCGGG was ligated into the 
polylinker of pGEX-6P-1 (Pharmacia). 100ng of pGEX-6P-1 was digested by Sal I 
and Not I, phenol extracted, ethanol and PEG precipitated. 1µM adaptor was ligated 
to 50ng of the cut vector in 10µl reaction volume. The ligation mix was used to 
transform chemo competent Sure cells. 5 colonies were picked to prepare mini 
preps, which were Xho I digested in order to check for adaptor insertion. 3 minipreps 
containing the adaptor were sequenced. 
 
Sequencing primers 
pGEX fw:   5’-GGC TGG CAA GCC ACG TTT GG 
pGEX rev:  5’-GAA ACG CGC GAG GCA GAT CG 
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 6.A11. Purification of active eukaryotic proteins from 
inclusion bodies in E. coli 
 Biotechniques: Vol XI, No. 6, December 1991, pp748-752  
The essence of this method is to purify the inclusion bodies followed by selective 
solubilization of the expressed protein.  
This protocol was designed for a 1L culture. However, one can scale the volumes up 
or down, depending on the type of experimentation performed. Both 100ml cultures 
and 500 ml cultures were prepared for this protocol (the results section specifies 
further).    
 
BUFFER A BUFFER P Buffer W
20mM Tris-HCl pH 7.5 PBS w/o Ca, Mg PBS w/o Ca, Mg 
20% Sucrose 5mM EDTA 25% Sucrose 
1mM EDTA 1X PIN, PMSF,--added fresh 5mM EDTA 
    1% Triton 
   
BUFFER R BUFFER D BUFFER U1
50Mm Tris-HCl pH 8.0 50mM Tris-Hcl pH 8.0 50mM Tris-HCl pH 8.0 
1mM DTT 5M Guanidium HCl 4M Urea 
20% Glycerol 5mM EDTA   
   
BUFFER U2
50mM Tris HCl pH 8.0
8M Urea 
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1. The cells from the 1L culture are transformed into two 500ml tubes and are 
pelleted by centrifugation at 5000rpm/min at 4 degrees C. To prevent 
contaminating the inclusion bodies by proteins from the outer membrane, the 
outer membrane is removed by resuspending the cell pellet from 1L culture in 
50ml BUFFER A. (If 100ml culture was prepared, only 5 ml Buffer A would be 
required. This down -scaling of volumes is required whenever a volume is 
indicated).    
2. Incubate on ice for 10 minutes. Pellet the cells by centrifugation at 
6000rpm/5min at 4 degrees C. Resuspend in 50ml of ice cold water. Leave 
on ice for 10 min. Centrifuge at 8200 rpm/5 min at 4 degrees C.    
3. Resuspend the pellet in 10ml Buffer P containing protease inhibitors.    
4. Sonicate the resuspended mixture 3x (50W) each with a 30sec. pulse with a 
30 sec. pause in between pulses. RNase T1 (1.3x103 U/10ml) + DNase I 
(400 ug/10ml) are added to the sonicated cell suspension and incubated at 
room temp for 10 min.    
5. The suspension is further diluted by addition of 40 ml of Washing Buffer P 
and the crude inclusion bodies are pelleted by centrifugation at 11,000 rpm 
for 30 min at 4 degrees C. Keep aliquot and assay the supernatant for 
proteins.    
6. The pellet (inclusion bodies) is suspended in 40 ml of Buffer W. Incubate on 
ice for 10 min and centrifuge at 15,000 rpm/5min at 4 degrees C. for 10 min. 
Keep aliquot of supernatant. Repeat this washing step and save the 
supernatant.    
7. Resuspend the pellet in 10ml of Buffer D. A brief sonication with a 5 sec. 
pulse (50W) facilitates the solubilization of the aggregated proteins (NOTE: 
the pellet may also be resuspended in 4M or 8M urea in addition to BUFFER 
D).    
8. The resultant suspension is incubated on ice for an additional 1 hour.    
9. Centrifuge at 10,500 rpm for 30 min at 4 degrees C. Add the supernatant to 
100ml of Renaturation Buffer R, and stir gently at 4 degrees C. over night to 
renature the proteins.    
10. The next day, the supernatant is clarified by centrifugation at 12,000 rpm for 
30 min at 4 degrees C. The supernatant contains highly purified expressed 
proteins.  
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 6.A12. Purification of GST Fused Proteins  
After Frangioni and Neel (1993), written by Chia Jin Ngee 
 
Many people have vented out frustration over insoluble GST-fused proteins. This is a 
protocol that for enzymatically active soluble GST-fused proteins.  All GST-fused 
proteins are rendered soluble with this technique though enzyme activitiy can range 
> from 30-90%. 
 
Materials/Reagents  
•  STE Buffer  
10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
150 mM NaCl  
• Lysozyme solution  
10 mg/ml in water (make fresh)  
• PBS  
• Elution Buffer    
50 mM Tris.Cl, pH 9.0 
20 mM GSH  
• 10% Sarkosyl in STE Buffer  
• 10% Triton X-100 in STE Buffer  
• 1 M DTT  
• 100 mM IPTG  
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  Method  
 Day 1 
1. 1. Set up an overnight culture in 50 ml 2XTY with 150 mg/ml of ampicillin.  
 Day 2 
2. Seed 5 ml of overnight culture to 500 ml 2XTY with 150 mg/ml of ampicillin.  
3. Grow at 37oC to an A600 of 0.6 to 0.8.  
4. Induce with 0.1 mM to 2 mM of IPTG. Grow for 3 hr at 37oC or grow overnight 
at room temperature. 
Lower IPTG concentrations and lower growing temperatures tend to produce 
greater solubility at the expense of yield.  
5. Pellet cells by centrifuging at 3000 g, 4oC for 10 min. Decant media and 
resuspend cells in 30 ml ice-cold PBS to wash. Transfer to a 40-ml Oak Ridge 
tube and centrifuge at 3000 g, 4oC for 10 min. Decant PBS.  
6. This is a convenient point to stop and to store pellets at -80oC. Else continue 
to lyse cells.  
7. Thaw pellet on ice if cells are frozen else proceed to the next step.  
8. Resuspend pellet in 10 ml of ice cold STE Buffer.  
9. Add 100 µl of freshly prepared lyozyme solution, incubate on ice for 15 min. 
Just before sonication, add 100 µl of 1 M DTT and 1.4 ml of 10% Sarkosyl. 
Mix thoroughly by inversion and sonicate for a total time of 1 min.  
10. Centrifuge 16,000 rpm  for 20 min on the SS34 rotor to pellet debris. Transfer 
supernatant to a 50-ml conical tube and discard the pellet. Add 4 ml of 10% 
Triton X-100 and top up with STE Buffer to 20 ml. The effective concentration 
of Sarkosyl and Triton X-100 will be 0.7% and 2% respectively. Incubate at 
room temperature for 30 min.  
11. Pour the lysate to 1 ml bed of prepared Glutathione Sepharose in PBS. 
Incubate at room temperature for 30 min to 1 hr with agitation. 
To prepare the 50% slurry, shake up the media and pipette 2 ml to a 50 ml 
tube. Fill to 50 ml with PBS, invert tube a few times. Centrifuge to 2000 rpm 
on a swing bucket centrifuge then switch off. Carefully suck off PBS and 
resuspend beads with 1 ml of PBS.  
12. Wash the beads with 3 X 50 ml of PBS. Finally resuspend in 5 ml of PBS. 
Pour to a dispo-column. Wash the 50-ml conical tube with an additional 5 ml 
of PBS. Pool with the first 5 ml in the dispo-column.  
To wash, use the same centrifugation technique for preparing the beads. 
When transferring beads to column, do not pipette but pour. The beads tend 
to stick to pipette tips.  
13. If desired, elute with 10 x 1 ml fractions of Elution Buffer. Determine desired 
fractions with SDS PAGE.  
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